filgotinib vs tofacitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: JAK · full Rheumatoid Arthritis pipeline
filgotinib · Jyseleca
Marketed by Gilead Sciences and partners
NCT02873936 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 449 patients; the primary endpoint, ACR20 response at week 12 (a validated rheumatoid-arthritis disease-activity measure), was significantly higher with both filgotinib doses than placebo (66.0% and 57.5% vs 31.1%, both p<0.001).
Next expected readout: April 2029 · NCT06687551 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001) (met)
Result source: NCT02889796
tofacitinib · Xeljanz
Marketed by Pfizer
NCT01262118 · Phase 1 · completed
This was a single-arm, open-label, unblinded study that tracked lipid biomarker levels before and after treatment in one group of patients, with no randomized or treated comparator arm and no statistical test of a treatment effect.
Next expected readout: January 2027 · NCT06945666 (registry estimate)
Reported efficacy
High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline; High-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 6; Cholesterol Ester Production Rate at Baseline; Cholesterol Ester Production Rate at Week 6: HDL cholesterol in the rheumatoid arthritis cohort on tofacitinib 10 mg twice daily: mean 54.30 mg/dL (SD 12.52) at baseline and 62.34 mg/dL (SD 15.24) at Week 6. The untreated healthy-volunteer cohort (63.43 mg/dL at baseline) is a reference group only. No statistical analysis is posted. (not_applicable)
Result source: NCT01262118
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | filgotinib | tofacitinib |
|---|---|---|
| ACR20 | 76.6% vs 49.9%+26.7 vs placeboNCT0288979651 other results
| 52.7% vs 31.2%+21.5 vs placeboNCT00856544273 other results
|
| ACR50 | 64.2% vs 66%−1.8 vs placeboNCT0288979687 other results
| 32.7% vs 16%+16.7 vs placeboNCT00847613275 other results
|
| ACR70 | 44.4% vs 37.7%+6.7 vs placeboNCT0288979687 other results
| 25.4% vs 12.1%vs MTXNCT01039688271 other results
|
| DAS28-CRP remission | 54.5% vs 50.8%+3.7 vs placeboNCT0288979635 other results
| 23.0% vs 5.2%+17.8 vs placeboNCT00847613174 other results
|
| HAQ-DI, change | -0.9 vs -0.7−0.2 vs placeboNCT0288979636 other results
| -0.5 vs -0.2−0.3 vs placeboNCT00814307233 other results
|
| Modified Sharp score, change | 0.2 vs 0.9−0.7 vs placeboNCT028897969 other results
| 0.1 vs 0.5−0.3 vs placeboNCT008476137 other results
|
ACR20
- filgotinib
- 76.6% vs 49.9%+26.7 vs placeboNCT02889796
51 other results
- 69.8% vs 49.9% NCT02889796
- 66% vs 31.1% NCT02873936
- 57.5% vs 31.1% NCT02873936
- 78.1% vs 71.4% NCT02886728
- 81% vs 71.4% NCT02886728
- 80.2% vs 71.4% NCT02886728
- 82.9% vs 85.9% NCT02889796
- 82.9% vs 86.9% NCT02889796
- 78.1% vs 59.2% NCT02889796
- 51.6% vs 31.8% NCT02889796
- 37.3% vs 14.9% NCT02889796
- 79.6% vs 85.9% NCT02889796
- 79.2% vs 86.9% NCT02889796
- 77.7% vs 59.2% NCT02889796
- 45.6% vs 31.8% NCT02889796
- 27.5% vs 14.9% NCT02889796
- 69.4% vs 34.5% NCT02873936
- 51.7% vs 25.7% NCT02873936
- 54.9% vs 34.5% NCT02873936
- 44.4% vs 25.7% NCT02873936
- 74.8% vs 61.8% NCT02886728
- 76.2% vs 68.3% NCT02886728
- 71.4% vs 59.4% NCT02886728
- 52.4% vs 33.4% NCT02886728
- 39.5% vs 16.6% NCT02886728
- 75% vs 61.8% NCT02886728
- 75.5% vs 68.3% NCT02886728
- 76.7% vs 59.4% NCT02886728
- 62.3% vs 33.4% NCT02886728
- 42.1% vs 16.6% NCT02886728
- 73.4% vs 61.8% NCT02886728
- 73.4% vs 68.3% NCT02886728
- 72% vs 59.4% NCT02886728
- 55.6% vs 33.4% NCT02886728
- 37.2% vs 16.6% NCT02886728
- 72.5% vs 29.2% NCT01894516
- 68.6% vs 44.2% NCT01888874
- 65.7% vs 29.2% NCT01894516
- 63.5% vs 44.2% NCT01888874
- 78.6% vs 44.2% NCT01888874
- 66.7% vs 29.2% NCT01894516
- 56.1% vs 44.2% NCT01888874
- 60% vs 44.2% NCT01888874
- 57% vs 44.2% NCT01888874
- 73.3% vs 41.9% NCT01888874
- 61.2% vs 41.9% NCT01888874
- 79.8% vs 41.9% NCT01888874
- 54.9% vs 41.9% NCT01888874
- 60% vs 41.9% NCT01888874
- 55.8% vs 41.9% NCT01888874
- 81% vs 40.9% NCT02885181
- tofacitinib
- 52.7% vs 31.2%+21.5 vs placeboNCT00856544
273 other results
- 51.5% vs 28.3% NCT00853385
- 51.5% vs 25.3% NCT00847613
- 59.8% vs 26.7% NCT00814307
- 41.7% vs 24.4% NCT00960440
- 58.3% vs 31.2% NCT00856544
- 52.5% vs 28.3% NCT00853385
- 61.8% vs 25.3% NCT00847613
- 65.7% vs 26.7% NCT00814307
- 48.1% vs 24.4% NCT00960440
- 52.7% vs 31.2% NCT00856544
- 50.8% vs 25.5% NCT00856544
- 56.3% vs 27.4% NCT00856544
- 60.7% vs 26.4% NCT00853385
- 56.3% vs 27.3% NCT00847613
- 56.9% vs 25.8% NCT00814307
- 54.0% vs 26.1% NCT00856544
- 46.5% vs 21.7% NCT00814307
- 38.6% vs 22.9% NCT00856544
- 41.2% vs 16.0% NCT00853385
- 41.4% vs 16.3% NCT00847613
- 42.4% vs 27.5% NCT00960440
- 29.6% vs 11.8% NCT00814307
- 27.3% vs 10.9% NCT00856544
- 27.7% vs 16.7% NCT00960440
- 58.3% vs 31.2% NCT00856544
- 57.9% vs 25.5% NCT00856544
- 64.7% vs 27.4% NCT00856544
- 58.7% vs 26.4% NCT00853385
- 66.3% vs 27.3% NCT00847613
- 60.7% vs 25.8% NCT00814307
- 64.4% vs 26.1% NCT00856544
- 52.1% vs 21.7% NCT00814307
- 48.5% vs 22.9% NCT00856544
- 45.9% vs 16.0% NCT00853385
- 52.1% vs 16.3% NCT00847613
- 44.4% vs 27.5% NCT00960440
- 39.2% vs 11.8% NCT00814307
- 32.3% vs 10.9% NCT00856544
- 32.8% vs 16.7% NCT00960440
- 49.5% vs 49.3% NCT00853385
- 67.8% vs 51.1% NCT01039688
- 49.5% vs 47.2% NCT00853385
- 72.1% vs 55.4% NCT01039688
- 68.8% vs 47.3% NCT01039688
- 71.3% vs 50.5% NCT01039688
- 64.2% vs 46.7% NCT01039688
- 69.9% vs 51.6% NCT01039688
- 65.0% vs 45.1% NCT01039688
- 63.6% vs 42.4% NCT01039688
- 49.3% vs 21.2% NCT01039688
- 64.2% vs 42.4% NCT01039688
- 49.5% vs 49.3% NCT00853385
- 71.6% vs 51.1% NCT01039688
- 50.5% vs 47.2% NCT00853385
- 73.6% vs 55.4% NCT01039688
- 66.2% vs 47.3% NCT01039688
- 76.1% vs 50.5% NCT01039688
- 66.0% vs 46.7% NCT01039688
- 77.9% vs 51.6% NCT01039688
- 62.2% vs 45.1% NCT01039688
- 71.6% vs 42.4% NCT01039688
- 58.3% vs 21.2% NCT01039688
- 64.2% vs 42.4% NCT01039688
- 73.1% vs 15.4% NCT00687193
- 61.2% vs 23.7% NCT00550446
- 96.3% vs 14.3% NCT00603512
- 56.3% vs 36.2% NCT00413660
- 70.5% vs 29.2% NCT00147498
- 84.9% vs 15.4% NCT00687193
- 72.1% vs 23.7% NCT00550446
- 80.8% vs 14.3% NCT00603512
- 58.1% vs 36.2% NCT00413660
- 76.8% vs 29.2% NCT00147498
- 56.3% vs 36.2% NCT00413660
- 90.7% vs 15.4% NCT00687193
- 71.9% vs 23.7% NCT00550446
- 56% vs 36.2% NCT00413660
- 81.2% vs 29.2% NCT00147498
- 67.9% vs 15.4% NCT00687193
- 45.1% vs 23.7% NCT00550446
- 77.8% vs 14.3% NCT00603512
- 55.9% vs 36.2% NCT00413660
- 37.7% vs 15.4% NCT00687193
- 31.5% vs 23.7% NCT00550446
- 64.3% vs 14.3% NCT00603512
- 47.1% vs 36.2% NCT00413660
- 57.1% vs 47.1% NCT00550446
- 59.2% vs 47.1% NCT00413660
- 69.4% vs 32.4% NCT00550446
- 57.7% vs 47.1% NCT00413660
- 67.3% vs 35.3% NCT00550446
- 53.5% vs 43.1% NCT00413660
- 57.1% vs 23.7% NCT00550446
- 67.3% vs 11.5% NCT00687193
- 63.3% vs 27.1% NCT00550446
- 96.3% vs 21.4% NCT00603512
- 54.9% vs 33.3% NCT00413660
- 50% vs 28.9% NCT00147498
- 63.3% vs 25.4% NCT00550446
- 57.8% vs 37.7% NCT00413660
- 61.5% vs 9.6% NCT00687193
- 40.8% vs 27.1% NCT00550446
- 88.9% vs 10.7% NCT00603512
- 46.5% vs 24.6% NCT00413660
- 63.9% vs 30.8% NCT00147498
- 34.6% vs 5.8% NCT00687193
- 32.6% vs 15.3% NCT00550446
- 63.0% vs 10.7% NCT00603512
- 31.0% vs 15.9% NCT00413660
- 50.8% vs 20% NCT00147498
- 29.6% vs 3.6% NCT00603512
- 27.9% vs 12.3% NCT00147498
- 73.8% vs 47.1% NCT00550446
- 66.2% vs 47.1% NCT00413660
- 73.8% vs 32.4% NCT00550446
- 62.2% vs 47.1% NCT00413660
- 70.5% vs 35.3% NCT00550446
- 64.9% vs 43.1% NCT00413660
- 75.4% vs 23.7% NCT00550446
- 86.8% vs 11.5% NCT00687193
- 65.6% vs 27.1% NCT00550446
- 56.8% vs 33.3% NCT00413660
- 55.4% vs 37.7% NCT00413660
- 81.1% vs 9.6% NCT00687193
- 46.0% vs 24.6% NCT00413660
- 66% vs 5.8% NCT00687193
- 70.6% vs 28.9% NCT00147498
- 75.4% vs 30.8% NCT00147498
- 68.1% vs 20% NCT00147498
- 56.5% vs 12.3% NCT00147498
- 62.7% vs 47.1% NCT00413660
- 64.2% vs 47.1% NCT00413660
- 64.2% vs 43.1% NCT00413660
- 56.3% vs 33.3% NCT00413660
- 50% vs 37.7% NCT00413660
- 51.3% vs 24.6% NCT00413660
- 33.8% vs 15.9% NCT00413660
- 80.8% vs 21.4% NCT00603512
- 63.9% vs 25.4% NCT00550446
- 52.5% vs 27.1% NCT00550446
- 76.9% vs 10.7% NCT00603512
- 50.8% vs 15.3% NCT00550446
- 50% vs 10.7% NCT00603512
- 31.1% vs 15.9% NCT00413660
- 38.5% vs 3.6% NCT00603512
- 68.4% vs 47.1% NCT00550446
- 65.3% vs 47.1% NCT00413660
- 71.9% vs 32.4% NCT00550446
- 61.3% vs 47.1% NCT00413660
- 71.9% vs 35.3% NCT00550446
- 62.7% vs 43.1% NCT00413660
- 75.4% vs 23.7% NCT00550446
- 87% vs 11.5% NCT00687193
- 71.9% vs 27.1% NCT00550446
- 64% vs 33.3% NCT00413660
- 66.1% vs 28.9% NCT00147498
- 66.7% vs 25.4% NCT00550446
- 56% vs 37.7% NCT00413660
- 77.8% vs 9.6% NCT00687193
- 63.2% vs 27.1% NCT00550446
- 54.7% vs 24.6% NCT00413660
- 75.4% vs 30.8% NCT00147498
- 53.7% vs 5.8% NCT00687193
- 38.6% vs 15.3% NCT00550446
- 40% vs 15.9% NCT00413660
- 71.0% vs 20% NCT00147498
- 43.5% vs 12.3% NCT00147498
- 58.8% vs 47.1% NCT00550446
- 65.5% vs 47.1% NCT00413660
- 64.7% vs 32.4% NCT00550446
- 67.3% vs 47.1% NCT00413660
- 58.8% vs 35.3% NCT00550446
- 60% vs 43.1% NCT00413660
- 37.3% vs 23.7% NCT00550446
- 62.3% vs 11.5% NCT00687193
- 47.1% vs 27.1% NCT00550446
- 66.7% vs 21.4% NCT00603512
- 54.4% vs 33.3% NCT00413660
- 47.1% vs 25.4% NCT00550446
- 54.4% vs 37.7% NCT00413660
- 47.2% vs 9.6% NCT00687193
- 37.3% vs 27.1% NCT00550446
- 55.6% vs 10.7% NCT00603512
- 45.6% vs 24.6% NCT00413660
- 34% vs 5.8% NCT00687193
- 31.4% vs 15.3% NCT00550446
- 40.7% vs 10.7% NCT00603512
- 36.8% vs 15.9% NCT00413660
- 14.8% vs 3.6% NCT00603512
- 35.1% vs 47.1% NCT00550446
- 59.2% vs 47.1% NCT00413660
- 45.9% vs 32.4% NCT00550446
- 59.2% vs 47.1% NCT00413660
- 51.4% vs 35.3% NCT00550446
- 63.3% vs 43.1% NCT00413660
- 35.2% vs 23.7% NCT00550446
- 37.7% vs 11.5% NCT00687193
- 37.0% vs 27.1% NCT00550446
- 67.9% vs 21.4% NCT00603512
- 50% vs 33.3% NCT00413660
- 38.9% vs 25.4% NCT00550446
- 44.3% vs 37.7% NCT00413660
- 35.8% vs 9.6% NCT00687193
- 22.2% vs 27.1% NCT00550446
- 50% vs 10.7% NCT00603512
- 37.1% vs 24.6% NCT00413660
- 18.9% vs 5.8% NCT00687193
- 16.7% vs 15.3% NCT00550446
- 82.6% vs 65.2% NCT01059864
- 76% vs 76.6% NCT01059864
- 0% vs 47.1% NCT00413660
- 0% vs 47.1% NCT00413660
- 0% vs 43.1% NCT00413660
- 0% vs 47.1% NCT00413660
- 0% vs 47.1% NCT00413660
- 0% vs 43.1% NCT00413660
- 0% vs 47.1% NCT00413660
- 0% vs 47.1% NCT00413660
- 0% vs 43.1% NCT00413660
- 32.1% vs 10.7% NCT00603512
- 21.4% vs 15.9% NCT00413660
- 28.6% vs 3.6% NCT00603512
- 60% vs 0% NCT00976599
- 71% vs 66.6% NCT02092467
- 70% vs 68% NCT02092467
- 69.9% vs 66.8% NCT02092467
- 68.7% vs 67.6% NCT02092467
- 67.4% vs 64.6% NCT02092467
- 67.3% vs 63.6% NCT02092467
- 65.6% vs 65.4% NCT02092467
- 57.2% vs 56% NCT02092467
- 65.7% vs 63.5% NCT02092467
- 66% vs 62.9% NCT02092467
- 64.1% vs 64.2% NCT02092467
- 64.3% vs 63.5% NCT02092467
- 62.3% vs 61.1% NCT02092467
- 61.6% vs 61.1% NCT02092467
- 62.2% vs 60.9% NCT02092467
- 53.6% vs 54.4% NCT02092467
- 44.9% vs 44% NCT02092467
- 36.8% vs 35.7% NCT02092467
- 29.8% vs 27.6% NCT02092467
- 23.2% vs 20.8% NCT02092467
- 16.7% vs 16% NCT02092467
- 11.2% vs 11.1% NCT02092467
- 5.8% vs 6.1% NCT02092467
- 1.8% vs 2.5% NCT02092467
- 0.3% vs 0.7% NCT02092467
- 68.1% vs 66.6% NCT02092467
- 69% vs 68% NCT02092467
- 68.9% vs 66.8% NCT02092467
- 69.5% vs 67.6% NCT02092467
- 66.9% vs 64.6% NCT02092467
- 68.1% vs 63.6% NCT02092467
- 65.5% vs 65.4% NCT02092467
- 59.5% vs 56% NCT02092467
- 63.3% vs 63.5% NCT02092467
- 63% vs 62.9% NCT02092467
- 61.7% vs 64.2% NCT02092467
- 61% vs 63.5% NCT02092467
- 60.5% vs 61.1% NCT02092467
- 57.9% vs 61.1% NCT02092467
- 58.2% vs 60.9% NCT02092467
- 49.3% vs 54.4% NCT02092467
- 40.3% vs 44% NCT02092467
- 33.3% vs 35.7% NCT02092467
- 27.2% vs 27.6% NCT02092467
- 22% vs 20.8% NCT02092467
- 16.3% vs 16% NCT02092467
- 11.4% vs 11.1% NCT02092467
- 6.9% vs 6.1% NCT02092467
- 2.5% vs 2.5% NCT02092467
- 1% vs 0.7% NCT02092467
ACR50
- filgotinib
- 64.2% vs 66%−1.8 vs placeboNCT02889796
87 other results
- 63.2% vs 63.4% NCT02889796
- 57.9% vs 33.3% NCT02889796
- 47.2% vs 19.8% NCT02889796
- 22.3% vs 5.9% NCT02889796
- 9.1% vs 1.1% NCT02889796
- 60.6% vs 66% NCT02889796
- 57.7% vs 63.4% NCT02889796
- 52.7% vs 33.3% NCT02889796
- 36.5% vs 19.8% NCT02889796
- 12.9% vs 5.9% NCT02889796
- 5.8% vs 1.1% NCT02889796
- 45.6% vs 18.9% NCT02873936
- 42.9% vs 14.9% NCT02873936
- 22.4% vs 7.4% NCT02873936
- 35.3% vs 18.9% NCT02873936
- 32% vs 14.9% NCT02873936
- 21.6% vs 7.4% NCT02873936
- 61.4% vs 48.3% NCT02886728
- 58.6% vs 48.6% NCT02886728
- 58.1% vs 45.7% NCT02886728
- 45.7% vs 28.4% NCT02886728
- 25.7% vs 9.4% NCT02886728
- 16.2% vs 2.9% NCT02886728
- 62.3% vs 48.3% NCT02886728
- 60.6% vs 48.6% NCT02886728
- 61.5% vs 45.7% NCT02886728
- 53.1% vs 28.4% NCT02886728
- 29.3% vs 9.4% NCT02886728
- 13% vs 2.9% NCT02886728
- 59.4% vs 48.3% NCT02886728
- 55.6% vs 48.6% NCT02886728
- 57% vs 45.7% NCT02886728
- 44.4% vs 28.4% NCT02886728
- 20.8% vs 9.4% NCT02886728
- 9.2% vs 2.9% NCT02886728
- 50% vs 16.3% NCT01888874
- 43.5% vs 11.1% NCT01894516
- 43% vs 15.1% NCT01888874
- 31.9% vs 5.6% NCT01894516
- 33.7% vs 12.8% NCT01888874
- 23.2% vs 4.2% NCT01894516
- 17.4% vs 7% NCT01888874
- 21.7% vs 4.2% NCT01894516
- 10.5% vs 5.8% NCT01888874
- 7.2% vs 1.4% NCT01894516
- 4.7% vs 1.2% NCT01888874
- 47.1% vs 16.3% NCT01888874
- 54.8% vs 16.3% NCT01888874
- 37.1% vs 11.1% NCT01894516
- 37.6% vs 15.1% NCT01888874
- 54.8% vs 15.1% NCT01888874
- 25.7% vs 5.6% NCT01894516
- 35.3% vs 12.8% NCT01888874
- 45.2% vs 12.8% NCT01888874
- 18.6% vs 4.2% NCT01894516
- 32.9% vs 7% NCT01888874
- 34.5% vs 7% NCT01888874
- 7.1% vs 4.2% NCT01894516
- 20% vs 5.8% NCT01888874
- 21.4% vs 5.8% NCT01888874
- 10% vs 1.4% NCT01894516
- 4.7% vs 1.2% NCT01888874
- 7.1% vs 1.2% NCT01888874
- 35.4% vs 16.3% NCT01888874
- 35.3% vs 16.3% NCT01888874
- 34.7% vs 11.1% NCT01894516
- 32.9% vs 15.1% NCT01888874
- 34.1% vs 15.1% NCT01888874
- 16.7% vs 5.6% NCT01894516
- 26.8% vs 12.8% NCT01888874
- 34.1% vs 12.8% NCT01888874
- 15.3% vs 4.2% NCT01894516
- 13.4% vs 7% NCT01888874
- 18.8% vs 7% NCT01888874
- 5.6% vs 4.2% NCT01894516
- 7.3% vs 5.8% NCT01888874
- 11.8% vs 5.8% NCT01888874
- 1.4% vs 1.4% NCT01894516
- 2.4% vs 1.2% NCT01888874
- 7.1% vs 1.2% NCT01888874
- 34.9% vs 16.3% NCT01888874
- 27.9% vs 15.1% NCT01888874
- 25.6% vs 12.8% NCT01888874
- 15.1% vs 7% NCT01888874
- 7% vs 5.8% NCT01888874
- 3.5% vs 1.2% NCT01888874
- 47.6% vs 22.7% NCT02885181
- tofacitinib
- 32.7% vs 16%+16.7 vs placeboNCT00847613
275 other results
- 32.7% vs 20% NCT00847613
- 33.8% vs 12.7% NCT00856544
- 36.7% vs 12.3% NCT00853385
- 32.4% vs 8.4% NCT00847613
- 28.0% vs 8.3% NCT00856544
- 31.1% vs 12.5% NCT00814307
- 27.3% vs 9.6% NCT00856544
- 34.2% vs 6.6% NCT00853385
- 28.8% vs 7.8% NCT00847613
- 26.5% vs 8.4% NCT00960440
- 26.1% vs 5.8% NCT00814307
- 23.1% vs 4.5% NCT00856544
- 17.4% vs 4.2% NCT00814307
- 11.6% vs 1.3% NCT00856544
- 14.9% vs 4.7% NCT00853385
- 16.8% vs 1.3% NCT00847613
- 12.9% vs 6.1% NCT00960440
- 5.8% vs 4.2% NCT00814307
- 5.8% vs 1.3% NCT00856544
- 7.7% vs 1.6% NCT00960440
- 41.1% vs 16% NCT00847613
- 44.0% vs 20% NCT00847613
- 36.6% vs 12.7% NCT00856544
- 34.7% vs 12.3% NCT00853385
- 43.7% vs 8.4% NCT00847613
- 33.3% vs 8.3% NCT00856544
- 36.8% vs 12.5% NCT00814307
- 34.0% vs 9.6% NCT00856544
- 27.6% vs 6.6% NCT00853385
- 36.3% vs 7.8% NCT00847613
- 27.8% vs 8.4% NCT00960440
- 33.9% vs 5.8% NCT00814307
- 29.8% vs 4.5% NCT00856544
- 24.0% vs 4.2% NCT00814307
- 18.1% vs 1.3% NCT00856544
- 16.3% vs 4.7% NCT00853385
- 18.4% vs 1.3% NCT00847613
- 17.3% vs 6.1% NCT00960440
- 12.9% vs 4.2% NCT00814307
- 8.1% vs 1.3% NCT00856544
- 5.5% vs 1.6% NCT00960440
- 36.7% vs 33.7% NCT00853385
- 49.9% vs 33.7% NCT01039688
- 35.7% vs 29.1% NCT00853385
- 49.9% vs 35.3% NCT01039688
- 50.7% vs 33.1% NCT01039688
- 46.6% vs 26.6% NCT01039688
- 48.0% vs 30.4% NCT01039688
- 40.1% vs 20.1% NCT01039688
- 49.0% vs 30.4% NCT01039688
- 32.6% vs 11.4% NCT01039688
- 18.0% vs 3.8% NCT01039688
- 49.3% vs 28.3% NCT01039688
- 35.7% vs 33.7% NCT00853385
- 55.6% vs 33.7% NCT01039688
- 37.2% vs 29.1% NCT00853385
- 56.9% vs 35.3% NCT01039688
- 54.3% vs 33.1% NCT01039688
- 56.4% vs 26.6% NCT01039688
- 51.8% vs 30.4% NCT01039688
- 50% vs 20.1% NCT01039688
- 50.5% vs 30.4% NCT01039688
- 40.1% vs 11.4% NCT01039688
- 28.0% vs 3.8% NCT01039688
- 49.2% vs 28.3% NCT01039688
- 36.7% vs 17.6% NCT00550446
- 39.4% vs 31.4% NCT00413660
- 32.7% vs 17.6% NCT00550446
- 38% vs 31.4% NCT00413660
- 34.7% vs 20.6% NCT00550446
- 38% vs 21.6% NCT00413660
- 46.2% vs 7.7% NCT00687193
- 38.8% vs 10.2% NCT00550446
- 81.5% vs 14.3% NCT00603512
- 36.6% vs 17.4% NCT00413660
- 34.7% vs 6.8% NCT00550446
- 44.2% vs 1.9% NCT00687193
- 24.5% vs 8.5% NCT00550446
- 70.4% vs 7.1% NCT00603512
- 32.4% vs 17.4% NCT00413660
- 17.9% vs 13.3% NCT00147498
- 14.3% vs 6.8% NCT00550446
- 31.0% vs 8.7% NCT00413660
- 32.8% vs 6.2% NCT00147498
- 28.8% vs 1.9% NCT00687193
- 10.2% vs 5.1% NCT00550446
- 29.6% vs 3.6% NCT00603512
- 11.3% vs 2.9% NCT00413660
- 32.8% vs 6.2% NCT00147498
- 11.5% vs 0% NCT00687193
- 8.2% vs 1.7% NCT00550446
- 25.9% vs 0% NCT00603512
- 5.6% vs 2.9% NCT00413660
- 9.8% vs 3.1% NCT00147498
- 0% vs 0% NCT00603512
- 6.6% vs 3.1% NCT00147498
- 45.9% vs 17.6% NCT00550446
- 39.2% vs 31.4% NCT00413660
- 42.6% vs 17.6% NCT00550446
- 40.5% vs 31.4% NCT00413660
- 42.6% vs 20.6% NCT00550446
- 36.5% vs 21.6% NCT00413660
- 69.8% vs 7.7% NCT00687193
- 45.9% vs 10.2% NCT00550446
- 50.8% vs 6.8% NCT00550446
- 62.3% vs 1.9% NCT00687193
- 29.5% vs 8.5% NCT00550446
- 36.1% vs 6.8% NCT00550446
- 54.7% vs 1.9% NCT00687193
- 31.1% vs 5.1% NCT00550446
- 32.1% vs 0% NCT00687193
- 18.0% vs 1.7% NCT00550446
- 25% vs 2.9% NCT00413660
- 15% vs 2.9% NCT00413660
- 57.7% vs 14.3% NCT00603512
- 28.4% vs 17.4% NCT00413660
- 50% vs 7.1% NCT00603512
- 28.4% vs 17.4% NCT00413660
- 27.0% vs 8.7% NCT00413660
- 34.6% vs 3.6% NCT00603512
- 20.3% vs 2.9% NCT00413660
- 26.9% vs 0% NCT00603512
- 4.0% vs 2.9% NCT00413660
- 45.1% vs 13.3% NCT00147498
- 50.7% vs 6.2% NCT00147498
- 42.0% vs 6.2% NCT00147498
- 29.0% vs 3.1% NCT00147498
- 18.8% vs 3.1% NCT00147498
- 46.3% vs 31.4% NCT00413660
- 47.8% vs 31.4% NCT00413660
- 41.8% vs 21.6% NCT00413660
- 36.3% vs 17.4% NCT00413660
- 32.5% vs 17.4% NCT00413660
- 27.5% vs 8.7% NCT00413660
- 7.7% vs 0% NCT00603512
- 54.4% vs 17.6% NCT00550446
- 46.7% vs 31.4% NCT00413660
- 59.6% vs 17.6% NCT00550446
- 48% vs 31.4% NCT00413660
- 56.1% vs 20.6% NCT00550446
- 40% vs 21.6% NCT00413660
- 72.2% vs 7.7% NCT00687193
- 50.9% vs 10.2% NCT00550446
- 44% vs 17.4% NCT00413660
- 43.9% vs 6.8% NCT00550446
- 66.7% vs 1.9% NCT00687193
- 49.1% vs 8.5% NCT00550446
- 41.3% vs 17.4% NCT00413660
- 30.4% vs 13.3% NCT00147498
- 42.1% vs 6.8% NCT00550446
- 32% vs 8.7% NCT00413660
- 53.6% vs 6.2% NCT00147498
- 46.3% vs 1.9% NCT00687193
- 40.4% vs 5.1% NCT00550446
- 26.7% vs 2.9% NCT00413660
- 42.0% vs 6.2% NCT00147498
- 22.2% vs 0% NCT00687193
- 17.5% vs 1.7% NCT00550446
- 17.3% vs 2.9% NCT00413660
- 23.2% vs 3.1% NCT00147498
- 8.7% vs 3.1% NCT00147498
- 44.1% vs 17.6% NCT00550446
- 34.5% vs 31.4% NCT00413660
- 44.1% vs 17.6% NCT00550446
- 45.5% vs 31.4% NCT00413660
- 38.2% vs 20.6% NCT00550446
- 43.6% vs 21.6% NCT00413660
- 26.4% vs 7.7% NCT00687193
- 25.5% vs 10.2% NCT00550446
- 44.4% vs 14.3% NCT00603512
- 29.4% vs 17.4% NCT00413660
- 17.6% vs 6.8% NCT00550446
- 37.7% vs 1.9% NCT00687193
- 21.6% vs 8.5% NCT00550446
- 29.6% vs 7.1% NCT00603512
- 32.4% vs 17.4% NCT00413660
- 15.7% vs 6.8% NCT00550446
- 29.4% vs 8.7% NCT00413660
- 22.6% vs 1.9% NCT00687193
- 13.7% vs 5.1% NCT00550446
- 22.2% vs 3.6% NCT00603512
- 16.2% vs 2.9% NCT00413660
- 9.4% vs 0% NCT00687193
- 7.8% vs 1.7% NCT00550446
- 7.4% vs 0% NCT00603512
- 5.9% vs 2.9% NCT00413660
- 3.7% vs 0% NCT00603512
- 10.8% vs 17.6% NCT00550446
- 44.9% vs 31.4% NCT00413660
- 18.9% vs 17.6% NCT00550446
- 38.8% vs 31.4% NCT00413660
- 18.9% vs 20.6% NCT00550446
- 38.8% vs 21.6% NCT00413660
- 13.5% vs 7.7% NCT00687193
- 11.1% vs 10.2% NCT00550446
- 32.1% vs 14.3% NCT00603512
- 22.9% vs 17.4% NCT00413660
- 13.0% vs 6.8% NCT00550446
- 11.5% vs 1.9% NCT00687193
- 13.0% vs 8.5% NCT00550446
- 28.6% vs 7.1% NCT00603512
- 17.1% vs 17.4% NCT00413660
- 14.8% vs 6.8% NCT00550446
- 10% vs 8.7% NCT00413660
- 9.6% vs 1.9% NCT00687193
- 9.3% vs 5.1% NCT00550446
- 10.7% vs 3.6% NCT00603512
- 4.3% vs 2.9% NCT00413660
- 1.9% vs 0% NCT00687193
- 1.9% vs 1.7% NCT00550446
- 7.1% vs 0% NCT00603512
- 1.4% vs 2.9% NCT00413660
- 67.4% vs 45.7% NCT01059864
- 48% vs 42.6% NCT01059864
- 0% vs 31.4% NCT00413660
- 0% vs 31.4% NCT00413660
- 0% vs 21.6% NCT00413660
- 0% vs 31.4% NCT00413660
- 0% vs 31.4% NCT00413660
- 0% vs 21.6% NCT00413660
- 0% vs 31.4% NCT00413660
- 0% vs 31.4% NCT00413660
- 0% vs 21.6% NCT00413660
- 7.1% vs 0% NCT00603512
- 40% vs 0% NCT00976599
- 43.4% vs 39.8% NCT02092467
- 42.6% vs 39.8% NCT02092467
- 44.8% vs 40.1% NCT02092467
- 41.6% vs 36.7% NCT02092467
- 43.5% vs 42% NCT02092467
- 36.3% vs 31.7% NCT02092467
- 41.7% vs 41.9% NCT02092467
- 27.6% vs 23.2% NCT02092467
- 42.7% vs 40.8% NCT02092467
- 42.6% vs 41.1% NCT02092467
- 41.2% vs 42% NCT02092467
- 40.2% vs 40.9% NCT02092467
- 41.4% vs 40.8% NCT02092467
- 40.9% vs 38.7% NCT02092467
- 40.7% vs 40.5% NCT02092467
- 35.8% vs 35.8% NCT02092467
- 29% vs 29.2% NCT02092467
- 24.1% vs 23.8% NCT02092467
- 19.5% vs 18.5% NCT02092467
- 13.7% vs 14.4% NCT02092467
- 10.4% vs 10.3% NCT02092467
- 6.9% vs 7.1% NCT02092467
- 3.6% vs 3.8% NCT02092467
- 1.1% vs 1.9% NCT02092467
- 0.2% vs 0.5% NCT02092467
- 44.9% vs 39.8% NCT02092467
- 44.7% vs 39.8% NCT02092467
- 45.9% vs 40.1% NCT02092467
- 42.2% vs 36.7% NCT02092467
- 44.2% vs 42% NCT02092467
- 38.5% vs 31.7% NCT02092467
- 42.8% vs 41.9% NCT02092467
- 31% vs 23.2% NCT02092467
- 42.3% vs 40.8% NCT02092467
- 41.3% vs 41.1% NCT02092467
- 41.8% vs 42% NCT02092467
- 42% vs 40.9% NCT02092467
- 38.9% vs 40.8% NCT02092467
- 40.4% vs 38.7% NCT02092467
- 39.7% vs 40.5% NCT02092467
- 33% vs 35.8% NCT02092467
- 26.4% vs 29.2% NCT02092467
- 22% vs 23.8% NCT02092467
- 18.6% vs 18.5% NCT02092467
- 14.4% vs 14.4% NCT02092467
- 10.4% vs 10.3% NCT02092467
- 7.1% vs 7.1% NCT02092467
- 4.7% vs 3.8% NCT02092467
- 1.4% vs 1.9% NCT02092467
- 0.4% vs 0.5% NCT02092467
ACR70
- filgotinib
- 44.4% vs 37.7%+6.7 vs placeboNCT02889796
87 other results
- 40.2% vs 34.6% NCT02889796
- 36.2% vs 14.9% NCT02889796
- 26.1% vs 6.7% NCT02889796
- 9.1% vs 1.5% NCT02889796
- 2.7% vs 0.4% NCT02889796
- 39% vs 37.7% NCT02889796
- 35.4% vs 34.6% NCT02889796
- 29.6% vs 14.9% NCT02889796
- 18.5% vs 6.7% NCT02889796
- 3.3% vs 1.5% NCT02889796
- 1.3% vs 0.4% NCT02889796
- 32% vs 8.1% NCT02873936
- 21.8% vs 6.8% NCT02873936
- 6.1% vs 2.7% NCT02873936
- 20.3% vs 8.1% NCT02873936
- 14.4% vs 6.8% NCT02873936
- 8.5% vs 2.7% NCT02873936
- 45.2% vs 29.8% NCT02886728
- 39.5% vs 32.2% NCT02886728
- 40% vs 26% NCT02886728
- 29% vs 13.2% NCT02886728
- 11.4% vs 3.8% NCT02886728
- 4.3% vs 0.7% NCT02886728
- 47.8% vs 29.8% NCT02886728
- 45.9% vs 32.2% NCT02886728
- 43.8% vs 26% NCT02886728
- 32.9% vs 13.2% NCT02886728
- 13% vs 3.8% NCT02886728
- 3.1% vs 0.7% NCT02886728
- 40.1% vs 29.8% NCT02886728
- 37.2% vs 32.2% NCT02886728
- 40.1% vs 26% NCT02886728
- 27.1% vs 13.2% NCT02886728
- 6.3% vs 3.8% NCT02886728
- 1.9% vs 0.7% NCT02886728
- 29.1% vs 9.3% NCT01888874
- 13% vs 2.8% NCT01894516
- 24.4% vs 8.1% NCT01888874
- 17.4% vs 2.8% NCT01894516
- 18.6% vs 7% NCT01888874
- 11.6% vs 1.4% NCT01894516
- 4.7% vs 3.5% NCT01888874
- 4.3% vs 2.8% NCT01894516
- 5.8% vs 1.2% NCT01888874
- 1.4% vs 0% NCT01894516
- 1.2% vs 1.2% NCT01888874
- 32.9% vs 9.3% NCT01888874
- 39.3% vs 9.3% NCT01888874
- 18.6% vs 2.8% NCT01894516
- 21.2% vs 8.1% NCT01888874
- 31% vs 8.1% NCT01888874
- 11.4% vs 2.8% NCT01894516
- 23.5% vs 7% NCT01888874
- 27.4% vs 7% NCT01888874
- 5.7% vs 1.4% NCT01894516
- 14.1% vs 3.5% NCT01888874
- 10.7% vs 3.5% NCT01888874
- 1.4% vs 2.8% NCT01894516
- 7.1% vs 1.2% NCT01888874
- 3.6% vs 1.2% NCT01888874
- 1.4% vs 0% NCT01894516
- 0% vs 1.2% NCT01888874
- 4.8% vs 1.2% NCT01888874
- 22% vs 9.3% NCT01888874
- 23.5% vs 9.3% NCT01888874
- 8.3% vs 2.8% NCT01894516
- 15.9% vs 8.1% NCT01888874
- 18.8% vs 8.1% NCT01888874
- 6.9% vs 2.8% NCT01894516
- 11% vs 7% NCT01888874
- 14.1% vs 7% NCT01888874
- 8.3% vs 1.4% NCT01894516
- 7.3% vs 3.5% NCT01888874
- 9.4% vs 3.5% NCT01888874
- 1.4% vs 2.8% NCT01894516
- 2.4% vs 1.2% NCT01888874
- 5.9% vs 1.2% NCT01888874
- 0% vs 0% NCT01894516
- 0% vs 1.2% NCT01888874
- 2.4% vs 1.2% NCT01888874
- 20.9% vs 9.3% NCT01888874
- 14% vs 8.1% NCT01888874
- 9.3% vs 7% NCT01888874
- 5.8% vs 3.5% NCT01888874
- 2.3% vs 1.2% NCT01888874
- 1.2% vs 1.2% NCT01888874
- 38.1% vs 13.6% NCT02885181
- tofacitinib
- 25.4% vs 12.1%vs MTXNCT01039688
271 other results
- 37.3% vs 12.1% NCT01039688
- 13.2% vs 3.2% NCT00856544
- 19.9% vs 1.9% NCT00853385
- 14.6% vs 1.3% NCT00847613
- 11.9% vs 3.2% NCT00856544
- 15.3% vs 5.8% NCT00814307
- 8.4% vs 1.9% NCT00856544
- 12.2% vs 1.9% NCT00853385
- 10.7% vs 2.6% NCT00847613
- 13.6% vs 1.5% NCT00960440
- 10.0% vs 3.3% NCT00814307
- 9% vs 1.3% NCT00856544
- 5.0% vs 1.7% NCT00814307
- 3.5% vs 0% NCT00856544
- 2.6% vs 0.9% NCT00853385
- 3.9% vs 0% NCT00847613
- 7.6% vs 0% NCT00960440
- 2.1% vs 0% NCT00814307
- 0.3% vs 0% NCT00856544
- 2.3% vs 0% NCT00960440
- 16.2% vs 3.2% NCT00856544
- 21.9% vs 1.9% NCT00853385
- 22.3% vs 1.3% NCT00847613
- 18.1% vs 3.2% NCT00856544
- 20.3% vs 5.8% NCT00814307
- 14.2% vs 1.9% NCT00856544
- 14.8% vs 1.9% NCT00853385
- 17.1% vs 2.6% NCT00847613
- 10.5% vs 1.5% NCT00960440
- 19.0% vs 3.3% NCT00814307
- 10.4% vs 1.3% NCT00856544
- 9.1% vs 1.7% NCT00814307
- 7.1% vs 0% NCT00856544
- 4.1% vs 0.9% NCT00853385
- 3.6% vs 0% NCT00847613
- 6.8% vs 0% NCT00960440
- 4.6% vs 0% NCT00814307
- 2.3% vs 0% NCT00856544
- 2.3% vs 0% NCT00960440
- 23.0% vs 16.6% NCT00853385
- 28.7% vs 15.4% NCT01039688
- 18.4% vs 11.1% NCT00853385
- 29.2% vs 13.2% NCT01039688
- 30.1% vs 17.0% NCT01039688
- 32.2% vs 15.9% NCT01039688
- 19.9% vs 5.5% NCT01039688
- 32.2% vs 17.6% NCT01039688
- 16.2% vs 3.3% NCT01039688
- 5.2% vs 0.6% NCT01039688
- 34.1% vs 15.4% NCT01039688
- 23.5% vs 16.6% NCT00853385
- 37.9% vs 15.4% NCT01039688
- 21.9% vs 11.1% NCT00853385
- 37.9% vs 13.2% NCT01039688
- 37.9% vs 17.0% NCT01039688
- 36.6% vs 15.9% NCT01039688
- 26.6% vs 5.5% NCT01039688
- 36.8% vs 17.6% NCT01039688
- 23.0% vs 3.3% NCT01039688
- 9.2% vs 0.6% NCT01039688
- 37.6% vs 15.4% NCT01039688
- 22.4% vs 11.8% NCT00550446
- 21.1% vs 9.8% NCT00413660
- 18.4% vs 8.8% NCT00550446
- 23.9% vs 13.7% NCT00413660
- 20.4% vs 0% NCT00550446
- 18.3% vs 9.8% NCT00413660
- 26.9% vs 1.9% NCT00687193
- 14.3% vs 3.4% NCT00550446
- 33.3% vs 3.6% NCT00603512
- 18.3% vs 5.8% NCT00413660
- 16.3% vs 1.7% NCT00550446
- 25% vs 1.9% NCT00687193
- 8.2% vs 1.7% NCT00550446
- 33.3% vs 3.6% NCT00603512
- 11.3% vs 5.8% NCT00413660
- 8.9% vs 8.9% NCT00147498
- 4.1% vs 1.7% NCT00550446
- 16.9% vs 4.3% NCT00413660
- 13.1% vs 3.1% NCT00147498
- 17.3% vs 0% NCT00687193
- 2.0% vs 1.7% NCT00550446
- 14.8% vs 0% NCT00603512
- 0% vs 1.4% NCT00413660
- 9.8% vs 1.5% NCT00147498
- 1.9% vs 0% NCT00687193
- 2.0% vs 0% NCT00550446
- 11.1% vs 0% NCT00603512
- 1.4% vs 0% NCT00413660
- 4.9% vs 1.5% NCT00147498
- 0% vs 0% NCT00603512
- 1.6% vs 0% NCT00147498
- 37.7% vs 11.8% NCT00550446
- 18.9% vs 9.8% NCT00413660
- 31.1% vs 8.8% NCT00550446
- 24.3% vs 13.7% NCT00413660
- 29.5% vs 0% NCT00550446
- 18.9% vs 9.8% NCT00413660
- 49.1% vs 1.9% NCT00687193
- 24.6% vs 3.4% NCT00550446
- 12.2% vs 5.8% NCT00413660
- 37.7% vs 1.9% NCT00687193
- 16.2% vs 5.8% NCT00413660
- 9.5% vs 4.3% NCT00413660
- 26.4% vs 0% NCT00687193
- 11.5% vs 1.7% NCT00550446
- 9.4% vs 0% NCT00687193
- 3.3% vs 0% NCT00550446
- 27.4% vs 8.9% NCT00147498
- 27.5% vs 3.1% NCT00147498
- 21.7% vs 1.5% NCT00147498
- 10.1% vs 1.5% NCT00147498
- 4.3% vs 0% NCT00147498
- 28.4% vs 9.8% NCT00413660
- 28.4% vs 13.7% NCT00413660
- 22.4% vs 9.8% NCT00413660
- 23.8% vs 5.8% NCT00413660
- 17.5% vs 5.8% NCT00413660
- 12.5% vs 4.3% NCT00413660
- 12.5% vs 1.4% NCT00413660
- 2.5% vs 0% NCT00413660
- 34.6% vs 3.6% NCT00603512
- 26.2% vs 1.7% NCT00550446
- 18.0% vs 1.7% NCT00550446
- 26.9% vs 3.6% NCT00603512
- 19.7% vs 1.7% NCT00550446
- 7.7% vs 0% NCT00603512
- 14.9% vs 1.4% NCT00413660
- 3.9% vs 0% NCT00603512
- 1.4% vs 0% NCT00413660
- 3.9% vs 0% NCT00603512
- 33.3% vs 11.8% NCT00550446
- 32% vs 9.8% NCT00413660
- 31.6% vs 8.8% NCT00550446
- 28% vs 13.7% NCT00413660
- 33.3% vs 0% NCT00550446
- 24% vs 9.8% NCT00413660
- 51.9% vs 1.9% NCT00687193
- 26.3% vs 3.4% NCT00550446
- 24% vs 5.8% NCT00413660
- 21.1% vs 1.7% NCT00550446
- 40.7% vs 1.9% NCT00687193
- 24.6% vs 1.7% NCT00550446
- 16% vs 5.8% NCT00413660
- 14.3% vs 8.9% NCT00147498
- 17.5% vs 1.7% NCT00550446
- 16% vs 4.3% NCT00413660
- 21.7% vs 3.1% NCT00147498
- 16.7% vs 0% NCT00687193
- 8.8% vs 1.7% NCT00550446
- 13.3% vs 1.4% NCT00413660
- 17.4% vs 1.5% NCT00147498
- 7.4% vs 0% NCT00687193
- 7.0% vs 0% NCT00550446
- 6.7% vs 0% NCT00413660
- 4.3% vs 1.5% NCT00147498
- 4.3% vs 0% NCT00147498
- 23.5% vs 11.8% NCT00550446
- 23.6% vs 9.8% NCT00413660
- 17.6% vs 8.8% NCT00550446
- 29.1% vs 13.7% NCT00413660
- 26.5% vs 0% NCT00550446
- 21.8% vs 9.8% NCT00413660
- 13.2% vs 1.9% NCT00687193
- 11.8% vs 3.4% NCT00550446
- 14.8% vs 3.6% NCT00603512
- 20.6% vs 5.8% NCT00413660
- 7.8% vs 1.7% NCT00550446
- 13.2% vs 1.9% NCT00687193
- 3.9% vs 1.7% NCT00550446
- 7.4% vs 3.6% NCT00603512
- 14.7% vs 5.8% NCT00413660
- 2.0% vs 1.7% NCT00550446
- 13.2% vs 4.3% NCT00413660
- 3.8% vs 0% NCT00687193
- 5.9% vs 1.7% NCT00550446
- 7.4% vs 0% NCT00603512
- 7.3% vs 1.4% NCT00413660
- 0% vs 0% NCT00687193
- 2.0% vs 0% NCT00550446
- 3.7% vs 0% NCT00603512
- 1.5% vs 0% NCT00413660
- 0% vs 0% NCT00603512
- 8.1% vs 11.8% NCT00550446
- 28.6% vs 9.8% NCT00413660
- 10.8% vs 8.8% NCT00550446
- 20.4% vs 13.7% NCT00413660
- 10.8% vs 0% NCT00550446
- 16.3% vs 9.8% NCT00413660
- 7.5% vs 1.9% NCT00687193
- 5.6% vs 3.4% NCT00550446
- 7.1% vs 3.6% NCT00603512
- 4.3% vs 5.8% NCT00413660
- 3.7% vs 1.7% NCT00550446
- 5.7% vs 1.9% NCT00687193
- 9.3% vs 1.7% NCT00550446
- 3.6% vs 3.6% NCT00603512
- 8.6% vs 5.8% NCT00413660
- 3.7% vs 1.7% NCT00550446
- 1.4% vs 4.3% NCT00413660
- 1.9% vs 0% NCT00687193
- 0% vs 1.7% NCT00550446
- 0% vs 0% NCT00687193
- 1.9% vs 0% NCT00550446
- 34.8% vs 30.4% NCT01059864
- 20% vs 19.1% NCT01059864
- 0% vs 9.8% NCT00413660
- 0% vs 13.7% NCT00413660
- 0% vs 9.8% NCT00413660
- 0% vs 9.8% NCT00413660
- 0% vs 13.7% NCT00413660
- 0% vs 9.8% NCT00413660
- 0% vs 9.8% NCT00413660
- 0% vs 13.7% NCT00413660
- 0% vs 9.8% NCT00413660
- 3.6% vs 0% NCT00603512
- 2.9% vs 1.4% NCT00413660
- 0% vs 0% NCT00603512
- 1.4% vs 0% NCT00413660
- 0% vs 0% NCT00603512
- 6.7% vs 0% NCT00976599
- 23.2% vs 19.6% NCT02092467
- 22.5% vs 20.1% NCT02092467
- 24.7% vs 21% NCT02092467
- 19.4% vs 16.1% NCT02092467
- 24.6% vs 22.4% NCT02092467
- 17.4% vs 13.7% NCT02092467
- 24.9% vs 22.2% NCT02092467
- 10.4% vs 7.8% NCT02092467
- 24% vs 22.6% NCT02092467
- 25.7% vs 23.6% NCT02092467
- 25.4% vs 24.7% NCT02092467
- 24.5% vs 24.5% NCT02092467
- 24.9% vs 24.2% NCT02092467
- 25.5% vs 23.3% NCT02092467
- 25.8% vs 23.6% NCT02092467
- 21.5% vs 20.5% NCT02092467
- 17.6% vs 16.4% NCT02092467
- 14.8% vs 13.7% NCT02092467
- 10.9% vs 11% NCT02092467
- 8.8% vs 8.1% NCT02092467
- 5.4% vs 6.3% NCT02092467
- 4% vs 4.4% NCT02092467
- 1.7% vs 2.4% NCT02092467
- 0.5% vs 1% NCT02092467
- 0.1% vs 0.3% NCT02092467
- 25.6% vs 19.6% NCT02092467
- 25.2% vs 20.1% NCT02092467
- 26.8% vs 21% NCT02092467
- 22.7% vs 16.1% NCT02092467
- 26.2% vs 22.4% NCT02092467
- 18.4% vs 13.7% NCT02092467
- 25.4% vs 22.2% NCT02092467
- 13.3% vs 7.8% NCT02092467
- 26.5% vs 22.6% NCT02092467
- 26.8% vs 23.6% NCT02092467
- 27.3% vs 24.7% NCT02092467
- 26.9% vs 24.5% NCT02092467
- 23.6% vs 24.2% NCT02092467
- 24.8% vs 23.3% NCT02092467
- 23.5% vs 23.6% NCT02092467
- 20.5% vs 20.5% NCT02092467
- 15.7% vs 16.4% NCT02092467
- 13.4% vs 13.7% NCT02092467
- 11.2% vs 11% NCT02092467
- 8.7% vs 8.1% NCT02092467
- 5.7% vs 6.3% NCT02092467
- 3.9% vs 4.4% NCT02092467
- 2.6% vs 2.4% NCT02092467
- 1% vs 1% NCT02092467
- 0.3% vs 0.3% NCT02092467
DAS28-CRP remission
- filgotinib
- 54.5% vs 50.8%+3.7 vs placeboNCT02889796
35 other results
- 50.3% vs 46.1% NCT02889796
- 48.4% vs 16.2% NCT02889796
- 34.1% vs 9.3% NCT02889796
- 13.7% vs 2.9% NCT02889796
- 5.1% vs 0.6% NCT02889796
- 44.8% vs 50.8% NCT02889796
- 42.9% vs 46.1% NCT02889796
- 35.2% vs 16.2% NCT02889796
- 23.8% vs 9.3% NCT02889796
- 8.8% vs 2.9% NCT02889796
- 1.7% vs 0.6% NCT02889796
- 30.6% vs 12.2% NCT02873936
- 22.4% vs 8.1% NCT02873936
- 10.2% vs 2.7% NCT02873936
- 26.1% vs 12.2% NCT02873936
- 25.5% vs 8.1% NCT02873936
- 11.8% vs 2.7% NCT02873936
- 46.2% vs 31.5% NCT02886728
- 43.3% vs 34.4% NCT02886728
- 42.4% vs 29.1% NCT02886728
- 29.5% vs 17.1% NCT02886728
- 19.5% vs 4.8% NCT02886728
- 10% vs 1% NCT02886728
- 53.4% vs 31.5% NCT02886728
- 52.6% vs 34.4% NCT02886728
- 54.1% vs 29.1% NCT02886728
- 39.7% vs 17.1% NCT02886728
- 16.6% vs 4.8% NCT02886728
- 7.2% vs 1% NCT02886728
- 43% vs 31.5% NCT02886728
- 42% vs 34.4% NCT02886728
- 42.5% vs 29.1% NCT02886728
- 31.9% vs 17.1% NCT02886728
- 15% vs 4.8% NCT02886728
- 4.3% vs 1% NCT02886728
- tofacitinib
- 23.0% vs 5.2%+17.8 vs placeboNCT00847613
174 other results
- 20.4% vs 5.2% NCT00847613
- 11.3% vs 2.0% NCT00847613
- 36.4% vs 5.2% NCT00847613
- 26.9% vs 5.2% NCT00847613
- 9.1% vs 2.0% NCT00847613
- 36.5% vs 20.6% NCT01039688
- 36.2% vs 17.4% NCT01039688
- 37.6% vs 19.6% NCT01039688
- 31.3% vs 15.2% NCT01039688
- 38.4% vs 19.0% NCT01039688
- 25.9% vs 9.8% NCT01039688
- 37.1% vs 17.4% NCT01039688
- 20.4% vs 5.4% NCT01039688
- 7.4% vs 2.7% NCT01039688
- 38.4% vs 18.5% NCT01039688
- 49.5% vs 20.6% NCT01039688
- 45.7% vs 17.4% NCT01039688
- 49.2% vs 19.6% NCT01039688
- 47.2% vs 15.2% NCT01039688
- 44.7% vs 19.0% NCT01039688
- 37.8% vs 9.8% NCT01039688
- 44.7% vs 17.4% NCT01039688
- 28.7% vs 5.4% NCT01039688
- 14.1% vs 2.7% NCT01039688
- 43.9% vs 18.5% NCT01039688
- 65.9% vs 30% NCT00550446
- 22% vs 15% NCT00550446
- 41.5% vs 19.4% NCT00413660
- 68.9% vs 16.7% NCT00550446
- 20% vs 5.6% NCT00550446
- 35.1% vs 13.9% NCT00413660
- 69.6% vs 35% NCT00550446
- 28.3% vs 15% NCT00550446
- 24.1% vs 8.1% NCT00413660
- 62.2% vs 6.7% NCT00550446
- 24.4% vs 6.7% NCT00550446
- 16.7% vs 6.7% NCT00413660
- 65.8% vs 3.3% NCT00550446
- 21.7% vs 4.3% NCT00550446
- 66.7% vs 9.7% NCT00550446
- 14.9% vs 4.4% NCT00550446
- 19.4% vs 6.9% NCT00413660
- 56.4% vs 5.9% NCT00550446
- 8.9% vs 1.9% NCT00550446
- 13.6% vs 3.5% NCT00413660
- 62.2% vs 5.7% NCT00550446
- 4.4% vs 1.9% NCT00550446
- 8.1% vs 3.3% NCT00413660
- 62.5% vs 2.7% NCT00550446
- 4.2% vs 0% NCT00550446
- 1.6% vs 3.3% NCT00413660
- 72.7% vs 30% NCT00550446
- 36.4% vs 15% NCT00550446
- 36.5% vs 19.4% NCT00413660
- 88.7% vs 16.7% NCT00550446
- 43.4% vs 5.6% NCT00550446
- 37.1% vs 13.9% NCT00413660
- 78.2% vs 35% NCT00550446
- 36.4% vs 15% NCT00550446
- 30.2% vs 8.1% NCT00413660
- 75.6% vs 6.7% NCT00550446
- 33.3% vs 6.7% NCT00550446
- 32.3% vs 6.7% NCT00413660
- 90.7% vs 3.3% NCT00550446
- 31.6% vs 4.3% NCT00550446
- 78.6% vs 9.7% NCT00550446
- 21.4% vs 4.4% NCT00550446
- 21.3% vs 6.9% NCT00413660
- 79.5% vs 5.9% NCT00550446
- 24.1% vs 1.9% NCT00550446
- 24.2% vs 3.5% NCT00413660
- 83.7% vs 5.7% NCT00550446
- 17.5% vs 1.9% NCT00550446
- 19.1% vs 3.3% NCT00413660
- 71.1% vs 2.7% NCT00550446
- 5% vs 0% NCT00550446
- 4.4% vs 3.3% NCT00413660
- 32.7% vs 19.4% NCT00413660
- 30.9% vs 13.9% NCT00413660
- 29.1% vs 8.1% NCT00413660
- 24.6% vs 6.7% NCT00413660
- 20.9% vs 6.9% NCT00413660
- 10.1% vs 3.5% NCT00413660
- 10% vs 3.3% NCT00413660
- 4.0% vs 3.3% NCT00413660
- 84.6% vs 30% NCT00550446
- 50% vs 15% NCT00550446
- 39.3% vs 19.4% NCT00413660
- 76.9% vs 16.7% NCT00550446
- 42.3% vs 5.6% NCT00550446
- 38.6% vs 13.9% NCT00413660
- 82.4% vs 35% NCT00550446
- 43.1% vs 15% NCT00550446
- 37.9% vs 8.1% NCT00413660
- 68.6% vs 6.7% NCT00550446
- 40.4% vs 6.7% NCT00550446
- 37.1% vs 6.7% NCT00413660
- 79.4% vs 3.3% NCT00550446
- 38.5% vs 4.3% NCT00550446
- 75% vs 9.7% NCT00550446
- 41.5% vs 4.4% NCT00550446
- 23.9% vs 6.9% NCT00413660
- 67.6% vs 5.9% NCT00550446
- 32.7% vs 1.9% NCT00550446
- 22.7% vs 3.5% NCT00413660
- 62.2% vs 5.7% NCT00550446
- 15.1% vs 1.9% NCT00550446
- 16.9% vs 3.3% NCT00413660
- 66.7% vs 2.7% NCT00550446
- 7.0% vs 0% NCT00550446
- 13.2% vs 3.3% NCT00413660
- 46.4% vs 30% NCT00550446
- 39.3% vs 15% NCT00550446
- 35.7% vs 19.4% NCT00413660
- 58.6% vs 16.7% NCT00550446
- 20.7% vs 5.6% NCT00550446
- 43.2% vs 13.9% NCT00413660
- 53.3% vs 35% NCT00550446
- 30% vs 15% NCT00550446
- 41.9% vs 8.1% NCT00413660
- 42.9% vs 6.7% NCT00550446
- 8.9% vs 6.7% NCT00550446
- 30.9% vs 6.7% NCT00413660
- 53.3% vs 3.3% NCT00550446
- 8.5% vs 4.3% NCT00550446
- 46.7% vs 9.7% NCT00550446
- 12.8% vs 4.4% NCT00550446
- 22.0% vs 6.9% NCT00413660
- 43.3% vs 5.9% NCT00550446
- 12.8% vs 1.9% NCT00550446
- 19.7% vs 3.5% NCT00413660
- 33.3% vs 5.7% NCT00550446
- 6.5% vs 1.9% NCT00550446
- 14.8% vs 3.3% NCT00413660
- 33.3% vs 2.7% NCT00550446
- 4% vs 0% NCT00550446
- 3.2% vs 3.3% NCT00413660
- 33.3% vs 30% NCT00550446
- 16.7% vs 15% NCT00550446
- 23.1% vs 19.4% NCT00413660
- 46.2% vs 16.7% NCT00550446
- 19.2% vs 5.6% NCT00550446
- 20.5% vs 13.9% NCT00413660
- 48.1% vs 35% NCT00550446
- 22.2% vs 15% NCT00550446
- 14.3% vs 8.1% NCT00413660
- 22.2% vs 6.7% NCT00550446
- 9.3% vs 6.7% NCT00550446
- 6.6% vs 6.7% NCT00413660
- 26.3% vs 3.3% NCT00550446
- 10.9% vs 4.3% NCT00550446
- 25.6% vs 9.7% NCT00550446
- 2.1% vs 4.4% NCT00550446
- 7.9% vs 6.9% NCT00413660
- 20.5% vs 5.9% NCT00550446
- 8.5% vs 1.9% NCT00550446
- 3.2% vs 3.5% NCT00413660
- 30% vs 5.7% NCT00550446
- 6% vs 1.9% NCT00550446
- 4.6% vs 3.3% NCT00413660
- 25.6% vs 2.7% NCT00550446
- 1.9% vs 0% NCT00550446
- 1.6% vs 3.3% NCT00413660
- 16.7% vs 19.4% NCT00413660
- 0% vs 13.9% NCT00413660
- 11.1% vs 8.1% NCT00413660
- 15.4% vs 19.4% NCT00413660
- 15.4% vs 13.9% NCT00413660
- 23.1% vs 8.1% NCT00413660
- 25% vs 19.4% NCT00413660
- 28.6% vs 13.9% NCT00413660
- 9.5% vs 8.1% NCT00413660
- 24% vs 22.4% NCT04413617
- 40.8% vs 22.4% NCT04413617
HAQ-DI, change
- filgotinib
- -0.9 vs -0.7−0.2 vs placeboNCT02889796
36 other results
- -0.9 vs -0.7 NCT02889796
- -0.8 vs -0.6 NCT02889796
- -0.7 vs -0.4 NCT02889796
- -0.4 vs -0.3 NCT02889796
- -0.3 vs -0.1 NCT02889796
- -0.8 vs -0.7 NCT02889796
- -0.8 vs -0.7 NCT02889796
- -0.8 vs -0.6 NCT02889796
- -0.6 vs -0.4 NCT02889796
- -0.3 vs -0.3 NCT02889796
- -0.2 vs -0.1 NCT02889796
- -0.8 vs -0.4 NCT02873936
- -0.6 vs -0.2 NCT02873936
- -0.4 vs -0.2 NCT02873936
- -0.6 vs -0.4 NCT02873936
- -0.5 vs -0.2 NCT02873936
- -0.3 vs -0.2 NCT02873936
- -0.9 vs -0.9 NCT02886728
- -0.9 vs -0.9 NCT02886728
- -0.9 vs -0.8 NCT02886728
- -0.8 vs -0.6 NCT02886728
- -0.5 vs -0.3 NCT02886728
- -0.3 vs -0.2 NCT02886728
- -1 vs -0.9 NCT02886728
- -1.0 vs -0.9 NCT02886728
- -0.9 vs -0.8 NCT02886728
- -0.8 vs -0.6 NCT02886728
- -0.6 vs -0.3 NCT02886728
- -0.4 vs -0.2 NCT02886728
- -1.0 vs -0.9 NCT02886728
- -0.9 vs -0.9 NCT02886728
- -0.9 vs -0.8 NCT02886728
- -0.8 vs -0.6 NCT02886728
- -0.5 vs -0.3 NCT02886728
- -0.4 vs -0.2 NCT02886728
- -0.7 vs -0.4 NCT02885181
- tofacitinib
- -0.5 vs -0.2−0.3 vs placeboNCT00814307
233 other results
- -0.5 vs -0.2 NCT00856544
- -0.5 vs -0.2 NCT00853385
- -0.3 vs -0.1 NCT00847613
- -0.4 vs -0.2 NCT00960440
- -0.5 vs -0.2 NCT00814307
- -0.5 vs -0.2 NCT00856544
- -0.6 vs -0.2 NCT00853385
- -0.4 vs -0.1 NCT00847613
- -0.4 vs -0.2 NCT00960440
- -0.9 vs -0.7 NCT01039688
- -0.8 vs -0.7 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -0.8 vs -0.6 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -0.8 vs -0.5 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -0.7 vs -0.3 NCT01039688
- -0.5 vs -0.2 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -1.0 vs -0.7 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -1.0 vs -0.7 NCT01039688
- -0.9 vs -0.6 NCT01039688
- -1.0 vs -0.7 NCT01039688
- -0.8 vs -0.5 NCT01039688
- -1 vs -0.7 NCT01039688
- -0.8 vs -0.3 NCT01039688
- -0.6 vs -0.2 NCT01039688
- -1.0 vs -0.7 NCT01039688
- -0.5 vs -0.4 NCT00550446
- -0.6 vs -0.4 NCT00413660
- -0.4 vs -0.3 NCT00550446
- -0.6 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00550446
- -0.5 vs -0.3 NCT00413660
- -0.6 vs 0.2 NCT00687193
- -0.4 vs -0.2 NCT00550446
- -0.5 vs -0.1 NCT00603512
- -0.5 vs -0.1 NCT00413660
- -0.5 vs -0.2 NCT00550446
- -0.5 vs 0.2 NCT00687193
- -0.4 vs -0.2 NCT00550446
- -0.5 vs 0.0 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.4 vs -0.2 NCT00147498
- -0.3 vs -0.2 NCT00550446
- -0.4 vs -0.1 NCT00413660
- -0.6 vs -0.2 NCT00147498
- -0.4 vs 0.0 NCT00687193
- -0.3 vs -0.1 NCT00550446
- -0.4 vs -0.1 NCT00603512
- -0.3 vs -0.1 NCT00413660
- -0.6 vs -0.1 NCT00147498
- -0.3 vs 0.1 NCT00687193
- -0.2 vs -0.0 NCT00550446
- -0.3 vs -0.0 NCT00603512
- -0.2 vs -0.1 NCT00413660
- -0.4 vs -0.1 NCT00147498
- -0.1 vs 0 NCT00603512
- -0.3 vs -0.1 NCT00147498
- -0.6 vs -0.4 NCT00550446
- -0.5 vs -0.4 NCT00413660
- -0.6 vs -0.3 NCT00550446
- -0.5 vs -0.4 NCT00413660
- -0.6 vs -0.3 NCT00550446
- -0.4 vs -0.3 NCT00413660
- -0.7 vs 0.2 NCT00687193
- -0.6 vs -0.2 NCT00550446
- -0.6 vs -0.2 NCT00550446
- -0.6 vs 0.2 NCT00687193
- -0.5 vs -0.2 NCT00550446
- -0.5 vs -0.2 NCT00550446
- -0.3 vs -0.1 NCT00413660
- -0.5 vs 0.0 NCT00687193
- -0.4 vs -0.1 NCT00550446
- -0.4 vs 0.1 NCT00687193
- -0.3 vs -0.0 NCT00550446
- -0.3 vs -0.1 NCT00413660
- -0.2 vs -0.1 NCT00413660
- -0.6 vs -0.1 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.5 vs 0.0 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.4 vs -0.1 NCT00603512
- -0.3 vs -0.1 NCT00413660
- -0.4 vs -0.0 NCT00603512
- -0.2 vs -0.1 NCT00413660
- -0.7 vs -0.2 NCT00147498
- -0.7 vs -0.2 NCT00147498
- -0.7 vs -0.1 NCT00147498
- -0.6 vs -0.1 NCT00147498
- -0.4 vs -0.1 NCT00147498
- -0.7 vs -0.4 NCT00413660
- -0.7 vs -0.4 NCT00413660
- -0.6 vs -0.3 NCT00413660
- -0.6 vs -0.1 NCT00413660
- -0.5 vs -0.1 NCT00413660
- -0.4 vs -0.1 NCT00413660
- -0.3 vs 0 NCT00603512
- -0.8 vs -0.4 NCT00550446
- -0.5 vs -0.4 NCT00413660
- -0.9 vs -0.3 NCT00550446
- -0.5 vs -0.4 NCT00413660
- -0.9 vs -0.3 NCT00550446
- -0.5 vs -0.3 NCT00413660
- -0.7 vs 0.2 NCT00687193
- -0.8 vs -0.2 NCT00550446
- -0.5 vs -0.1 NCT00413660
- -0.8 vs -0.2 NCT00550446
- -0.6 vs 0.2 NCT00687193
- -0.7 vs -0.2 NCT00550446
- -0.4 vs -0.1 NCT00413660
- -0.6 vs -0.2 NCT00147498
- -0.7 vs -0.2 NCT00550446
- -0.3 vs -0.1 NCT00413660
- -0.7 vs -0.2 NCT00147498
- -0.5 vs 0.0 NCT00687193
- -0.6 vs -0.1 NCT00550446
- -0.3 vs -0.1 NCT00413660
- -0.6 vs -0.1 NCT00147498
- -0.4 vs 0.1 NCT00687193
- -0.4 vs -0.0 NCT00550446
- -0.2 vs -0.1 NCT00413660
- -0.5 vs -0.1 NCT00147498
- -0.3 vs -0.1 NCT00147498
- -0.5 vs -0.4 NCT00550446
- -0.5 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00550446
- -0.6 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00550446
- -0.6 vs -0.3 NCT00413660
- -0.4 vs 0.2 NCT00687193
- -0.4 vs -0.2 NCT00550446
- -0.4 vs -0.1 NCT00603512
- -0.5 vs -0.1 NCT00413660
- -0.3 vs -0.2 NCT00550446
- -0.4 vs 0.2 NCT00687193
- -0.4 vs -0.2 NCT00550446
- -0.3 vs 0.0 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.3 vs -0.2 NCT00550446
- -0.4 vs -0.1 NCT00413660
- -0.3 vs 0.0 NCT00687193
- -0.3 vs -0.1 NCT00550446
- -0.3 vs -0.1 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.1 vs 0.1 NCT00687193
- -0.3 vs -0.0 NCT00550446
- -0.2 vs -0.0 NCT00603512
- -0.2 vs -0.1 NCT00413660
- -0.1 vs 0 NCT00603512
- -0.6 vs -0.4 NCT00550446
- -0.6 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00550446
- -0.6 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00550446
- -0.5 vs -0.3 NCT00413660
- -0.2 vs 0.2 NCT00687193
- -0.3 vs -0.2 NCT00550446
- -0.4 vs -0.1 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.4 vs -0.2 NCT00550446
- -0.2 vs 0.2 NCT00687193
- -0.3 vs -0.2 NCT00550446
- -0.4 vs 0.0 NCT00603512
- -0.3 vs -0.1 NCT00413660
- -0.3 vs -0.2 NCT00550446
- -0.3 vs -0.1 NCT00413660
- -0.1 vs 0.0 NCT00687193
- -0.1 vs -0.1 NCT00550446
- -0.2 vs -0.1 NCT00603512
- -0.2 vs -0.1 NCT00413660
- -0.1 vs 0.1 NCT00687193
- -0.1 vs -0.0 NCT00550446
- -0.1 vs -0.0 NCT00603512
- -0.1 vs -0.1 NCT00413660
- -0.3 vs -0.2 NCT01484561
- 0.1 vs -0.1 NCT01484561
- -0.4 vs -0.0 NCT01484561
- -0.5 vs -0.4 NCT00413660
- -0.4 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00413660
- -0.2 vs -0.4 NCT00413660
- -0.1 vs -0.4 NCT00413660
- -0.1 vs -0.3 NCT00413660
- -0.2 vs -0.4 NCT00413660
- -0.2 vs -0.4 NCT00413660
- -0.2 vs -0.3 NCT00413660
- -0.1 vs 0 NCT00603512
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.4 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.4 vs -0.4 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.5 vs -0.4 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.5 vs -0.4 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
Modified Sharp score, change
- filgotinib
- 0.2 vs 0.9−0.7 vs placeboNCT02889796
9 other results
- 0.1 vs 0.4 NCT02889796
- 0.5 vs 0.9 NCT02889796
- 0.2 vs 0.4 NCT02889796
- 0.3 vs 0.8 NCT02886728
- -0.0 vs 0.5 NCT02886728
- 0.3 vs 0.8 NCT02886728
- 0.2 vs 0.5 NCT02886728
- 0.2 vs 0.8 NCT02886728
- 0.2 vs 0.5 NCT02886728
- tofacitinib
- 0.1 vs 0.5−0.3 vs placeboNCT00847613
7 other results
- 0.1 vs 0.5 NCT00847613
- 0.2 vs 0.7 NCT01039688
- 0.1 vs 0.7 NCT01039688
- 0.4 vs 1.2 NCT01039688
- 0.6 vs 2.1 NCT01039688
- 0.2 vs 1.2 NCT01039688
- 0.3 vs 2.1 NCT01039688
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
23 other shared endpoints and safety
Coverage. filgotinib: 27 of 27 rows · tofacitinib: 27 of 27 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | filgotinib Rows use multiple source trials | tofacitinib Rows use multiple source trials |
|---|---|---|
| ACR/EULAR Remission responder rate · % of participants No placebo or comparator arm | 17.7% (n=497) @ 48wka,b,c,d NCT02065700 · Phase 2 · registry result, not featured evidence show 3 more doses20.7% (n=497) @ 48wk NCT02065700 · Phase 2 · registry result, not featured evidence 14% (n=242) @ 48wk NCT02065700 · Phase 2 · registry result, not featured evidence 16.7% (n=242) @ 48wk NCT02065700 · Phase 2 · registry result, not featured evidence | 22.35% (n=264) @ 48wk11 mga,b,c,d NCT02831855 · Phase 4 · registry result, not featured evidence · combination show 1 more dose23.68% (n=266) @ 48wk11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination |
| ACR20 responder rate · % of participants No placebo or comparator arm | 36.6% (n=497) @ 288wka,e,c,d NCT02065700 · Phase 2 · registry result, not featured evidence show 3 more doses87.9% (n=497) @ 288wk NCT02065700 · Phase 2 · registry result, not featured evidence 38.8% (n=242) @ 288wk NCT02065700 · Phase 2 · registry result, not featured evidence 85.5% (n=242) @ 288wk NCT02065700 · Phase 2 · registry result, not featured evidence | 100% (n=381) @ 288wk5 mg BIDa,e,c,d NCT00661661 · Phase 3 · registry result, not featured evidence show 1 more dose0% (n=105) @ 288wk10 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence |
| ACR50 responder rate · % of participants No placebo or comparator arm | 29.8% (n=497) @ 288wka,e,c,d NCT02065700 · Phase 2 · registry result, not featured evidence show 3 more doses70.8% (n=497) @ 288wk NCT02065700 · Phase 2 · registry result, not featured evidence 33.5% (n=242) @ 288wk NCT02065700 · Phase 2 · registry result, not featured evidence 73.6% (n=242) @ 288wk NCT02065700 · Phase 2 · registry result, not featured evidence | 100% (n=381) @ 288wk5 mg BIDa,e,c,d NCT00661661 · Phase 3 · registry result, not featured evidence show 1 more dose0% (n=105) @ 288wk10 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence |
| ACR70 responder rate · % of participants No placebo or comparator arm | 22.1% (n=497) @ 288wka,e,c,d NCT02065700 · Phase 2 · registry result, not featured evidence show 3 more doses52.4% (n=497) @ 288wk NCT02065700 · Phase 2 · registry result, not featured evidence 24.8% (n=242) @ 288wk NCT02065700 · Phase 2 · registry result, not featured evidence 54.5% (n=242) @ 288wk NCT02065700 · Phase 2 · registry result, not featured evidence | 66.7% (n=381) @ 288wk5 mg BIDa,e,c,d NCT00661661 · Phase 3 · registry result, not featured evidence show 1 more dose0% (n=105) @ 288wk10 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence |
| Boolean Remission responder rate · % of participants | 11.6% (n=86) vs 1.2% (n=86) placebo @ 24wk200 mg QDa,b,c,d,f NCT01888874 · Phase 2 · registry result, not featured evidence show 5 more doses19% (n=84) vs 1.2% (n=86) placebo @ 24wk100 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 8.2% (n=85) vs 1.2% (n=86) placebo @ 24wk100 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 3.5% (n=85) vs 1.2% (n=86) placebo @ 24wk50 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 11% (n=82) vs 1.2% (n=86) placebo @ 24wk50 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 5.8% (n=86) vs 1.2% (n=86) placebo @ 24wk25 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence | 8.33% (n=1455) vs 13.33% (n=1451) TNFi @ 312wk5 mg BIDa,b,c,d,f NCT02092467 · Phase 4 show 1 more dose22.22% (n=1456) vs 13.33% (n=1451) TNFi @ 312wk10 mg BID NCT02092467 · Phase 4 |
| CDAI absolute change · score | -33.6 vs -31.2 MTX score @ 52wk200 mga,g,c NCT02886728 · Phase 3 · monotherapy show 2 more doses-33.8 vs -31.2 MTX score @ 52wk200 mg NCT02886728 · Phase 3 · combination -31.9 vs -31.2 MTX score @ 52wk100 mg NCT02886728 · Phase 3 · combination | -28.52 vs -27.73 TNFi score @ 52wk5 mg BIDa,g,c NCT02092467 · Phase 4 show 1 more dose-29.38 vs -27.73 TNFi score @ 52wk10 mg BID NCT02092467 · Phase 4 |
| CDAI absolute change · score No placebo or comparator arm | -28.102 score @ 24wk200 mg QDa,b,c,d,h NCT01894516 · Phase 2 · registry result, not featured evidence show 2 more doses-29.502 score @ 24wk100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence -22.278 score @ 24wk50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence | 2.97 score @ 48wk11 mga,b,c,d,h NCT02831855 · Phase 4 · registry result, not featured evidence · combination show 1 more dose0.84 score @ 48wk11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination |
| CRP Change absolute change · mg | -10.87 vs -1.5 placebo mg @ 24wk200 mga,i,c,d NCT02873936 · Phase 3 show 1 more dose-11.12 vs -1.5 placebo mg @ 24wk100 mg NCT02873936 · Phase 3 | -19.43 vs -4.18 placebo mg @ 24wk5 mga,i,c,d NCT00550446 · Phase 2 · registry result, not featured evidence show 4 more doses-10.5 vs -4.18 placebo mg @ 24wk10 mg NCT00550446 · Phase 2 · registry result, not featured evidence -20.43 vs -4.18 placebo mg @ 24wk15 mg NCT00550446 · Phase 2 · registry result, not featured evidence -2.25 vs -4.18 placebo mg @ 24wk3 mg NCT00550446 · Phase 2 · registry result, not featured evidence -4.19 vs -4.18 placebo mg @ 24wk1 mg NCT00550446 · Phase 2 · registry result, not featured evidence |
| DAS Low Disease Activity responder rate · % of participants | 65.7% (n=210) vs 47.6% (n=416) MTX @ 52wk200 mga,c NCT02886728 · Phase 3 · monotherapy show 2 more doses69% (n=416) vs 47.6% (n=416) MTX @ 52wk200 mg NCT02886728 · Phase 3 · combination 59.9% (n=207) vs 47.6% (n=416) MTX @ 52wk100 mg NCT02886728 · Phase 3 · combination | 52.59% (n=367) vs 32.61% (n=184) MTX @ 52wk5 mg BIDa,c NCT01039688 · Phase 3 show 3 more doses33.33% (n=342) vs 18.71% (n=171) MTX @ 52wk5 mg BID NCT01039688 · Phase 3 64.97% (n=394) vs 32.61% (n=184) MTX @ 52wk10 mg BID NCT01039688 · Phase 3 41.13% (n=372) vs 18.71% (n=171) MTX @ 52wk10 mg BID NCT01039688 · Phase 3 |
| DAS28-CRP absolute change · score | -3.3 vs -2.8 MTX score @ 52wk200 mga,c NCT02886728 · Phase 3 · monotherapy show 2 more doses-3.4 vs -2.8 MTX score @ 52wk200 mg NCT02886728 · Phase 3 · combination -3.1 vs -2.8 MTX score @ 52wk100 mg NCT02886728 · Phase 3 · combination | -2.52 vs -1.99 MTX score @ 52wk5 mg BIDa,c NCT01039688 · Phase 3 show 1 more dose-2.85 vs -1.99 MTX score @ 52wk10 mg BID NCT01039688 · Phase 3 |
| FACIT - Fatigue absolute value · score | 39.8 vs 39.4 placebo score @ 52wk200 mga,c,d NCT02889796 · Phase 3 show 1 more dose39.8 vs 39.4 placebo score @ 52wk100 mg NCT02889796 · Phase 3 | 37.85 vs 35.99 MTX score @ 52wk5 mg BIDa,c,d NCT01039688 · Phase 3 show 1 more dose38.95 vs 35.99 MTX score @ 52wk10 mg BID NCT01039688 · Phase 3 |
| FACIT-Fatigue absolute change · score | 11.5 vs 11.3 MTX score @ 52wk200 mga,c NCT02886728 · Phase 3 · monotherapy show 2 more doses11.7 vs 11.3 MTX score @ 52wk200 mg NCT02886728 · Phase 3 · combination 11.9 vs 11.3 MTX score @ 52wk100 mg NCT02886728 · Phase 3 · combination | 8.75 vs 6.89 MTX score @ 52wk5 mg BIDa,c NCT01039688 · Phase 3 show 1 more dose9.18 vs 6.89 MTX score @ 52wk10 mg BID NCT01039688 · Phase 3 |
| FACIT-Fatigue absolute change · score No placebo or comparator arm | 13.7 score @ 24wk200 mg QDa,e,c,d NCT01894516 · Phase 2 · registry result, not featured evidence show 2 more doses11.3 score @ 24wk100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 10 score @ 24wk50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence | 34.58 score @ 24wk5 mga,e,c,d NCT00814307 · Phase 3 show 1 more dose36.3 score @ 24wk10 mg NCT00814307 · Phase 3 |
| HAQ-DI responder rate · % of participants | 75.8% (n=475) vs 81.6% (n=190) placebo @ 52wk200 mga,c,d NCT02889796 · Phase 3 show 1 more dose73% (n=480) vs 81.6% (n=190) placebo @ 52wk100 mg NCT02889796 · Phase 3 | 68.03% (n=366) vs 58.7% (n=184) MTX @ 52wk5 mg BIDa,c,d NCT01039688 · Phase 3 show 5 more doses65.03% (n=366) vs 52.72% (n=184) MTX @ 52wk5 mg BID NCT01039688 · Phase 3 59.56% (n=366) vs 45.65% (n=184) MTX @ 52wk5 mg BID NCT01039688 · Phase 3 71.43% (n=392) vs 58.7% (n=184) MTX @ 52wk10 mg BID NCT01039688 · Phase 3 67.35% (n=392) vs 52.72% (n=184) MTX @ 52wk10 mg BID NCT01039688 · Phase 3 63.01% (n=392) vs 45.65% (n=184) MTX @ 52wk10 mg BID NCT01039688 · Phase 3 |
| Patient Assessment of Arthritis Pain absolute change · score | -30 vs -14 placebo score @ 12wk200 mga,i,c,d NCT02873936 · Phase 3 show 1 more dose-27 vs -14 placebo score @ 12wk100 mg NCT02873936 · Phase 3 | -34.37 vs -1.06 placebo score @ 12wk5 mga,i,c,d NCT00687193 · Phase 2 · registry result, not featured evidence show 4 more doses-42.91 vs -1.06 placebo score @ 12wk10 mg NCT00687193 · Phase 2 · registry result, not featured evidence -43.79 vs -1.06 placebo score @ 12wk15 mg NCT00687193 · Phase 2 · registry result, not featured evidence -22.33 vs -1.06 placebo score @ 12wk3 mg NCT00687193 · Phase 2 · registry result, not featured evidence -18.38 vs -1.06 placebo score @ 12wk1 mg NCT00687193 · Phase 2 · registry result, not featured evidence |
| Patient Global Assessment absolute change · score | -31 vs -14 placebo score @ 12wk200 mga,i,c,d NCT02873936 · Phase 3 show 1 more dose-27 vs -14 placebo score @ 12wk100 mg NCT02873936 · Phase 3 | -34.59 vs -1.02 placebo score @ 12wk5 mga,i,c,d NCT00687193 · Phase 2 · registry result, not featured evidence show 4 more doses-43.55 vs -1.02 placebo score @ 12wk10 mg NCT00687193 · Phase 2 · registry result, not featured evidence -41.86 vs -1.02 placebo score @ 12wk15 mg NCT00687193 · Phase 2 · registry result, not featured evidence -20.91 vs -1.02 placebo score @ 12wk3 mg NCT00687193 · Phase 2 · registry result, not featured evidence -16.29 vs -1.02 placebo score @ 12wk1 mg NCT00687193 · Phase 2 · registry result, not featured evidence |
| Physician Global Assessment absolute change · score | -53 vs -41 placebo score @ 24wk200 mga,i,c NCT02873936 · Phase 3 show 1 more dose-45 vs -41 placebo score @ 24wk100 mg NCT02873936 · Phase 3 | -47.31 vs -43.42 PF-06651600 score @ 24wk11mg MRa,i,c NCT04413617 · Phase 2 · registry result, not featured evidence show 1 more dose-47.5 vs -43.42 PF-06651600 score @ 24wk400mg MR + 11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence · combination |
| SDAI absolute change · score | -35 vs -32 MTX score @ 52wk200 mga,g,c NCT02886728 · Phase 3 · monotherapy show 2 more doses-35.2 vs -32 MTX score @ 52wk200 mg NCT02886728 · Phase 3 · combination -33 vs -32 MTX score @ 52wk100 mg NCT02886728 · Phase 3 · combination | -29.56 vs -28.71 TNFi score @ 52wk5 mg BIDa,g,c NCT02092467 · Phase 4 show 1 more dose-30.46 vs -28.71 TNFi score @ 52wk10 mg BID NCT02092467 · Phase 4 |
| SDAI absolute change · score No placebo or comparator arm | -29.564 score @ 24wk200 mg QDa,b,c,d,h NCT01894516 · Phase 2 · registry result, not featured evidence show 2 more doses-30.983 score @ 24wk100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence -23.16 score @ 24wk50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence | 3.16 score @ 48wk11 mga,b,c,d,h NCT02831855 · Phase 4 · registry result, not featured evidence · combination show 1 more dose0.94 score @ 48wk11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination |
| SF-36 MCS absolute change · score | 6.1 vs 6.5 MTX score @ 52wk200 mga,c NCT02886728 · Phase 3 · monotherapy show 2 more doses6.2 vs 6.5 MTX score @ 52wk200 mg NCT02886728 · Phase 3 · combination 6.8 vs 6.5 MTX score @ 52wk100 mg NCT02886728 · Phase 3 · combination | 6.21 vs 4.72 MTX score @ 52wk5 mg BIDa,c NCT01039688 · Phase 3 show 1 more dose6.62 vs 4.72 MTX score @ 52wk10 mg BID NCT01039688 · Phase 3 |
| SF-36 MCS absolute value · score | 50.6 vs 50.8 placebo score @ 52wk200 mga,c,d NCT02889796 · Phase 3 show 1 more dose51.5 vs 50.8 placebo score @ 52wk100 mg NCT02889796 · Phase 3 | 47.04 vs 45.71 MTX score @ 52wk5 mg BIDa,c,d NCT01039688 · Phase 3 show 1 more dose48.05 vs 45.71 MTX score @ 52wk10 mg BID NCT01039688 · Phase 3 |
| SF-36 PCS absolute change · score | 11.9 vs 11.2 MTX score @ 52wk200 mga,c NCT02886728 · Phase 3 · monotherapy show 2 more doses13.4 vs 11.2 MTX score @ 52wk200 mg NCT02886728 · Phase 3 · combination 12 vs 11.2 MTX score @ 52wk100 mg NCT02886728 · Phase 3 · combination | 10.3 vs 7.48 MTX score @ 52wk5 mg BIDa,c NCT01039688 · Phase 3 show 1 more dose12.35 vs 7.48 MTX score @ 52wk10 mg BID NCT01039688 · Phase 3 |
| SF-36 PCS absolute value · score | 45.6 vs 45.1 placebo score @ 52wk200 mga,c,d NCT02889796 · Phase 3 show 1 more dose45.1 vs 45.1 placebo score @ 52wk100 mg NCT02889796 · Phase 3 | 43.65 vs 41.27 MTX score @ 52wk5 mg BIDa,c,d NCT01039688 · Phase 3 show 1 more dose45.72 vs 41.27 MTX score @ 52wk10 mg BID NCT01039688 · Phase 3 |
| Dropout rate | 8.8%200 mgj NCT02873936 · Phase 3 show 26 more results15%100 mg NCT02873936 · Phase 3 17.1%200 mg NCT02886728 · Phase 3 · monotherapy 17.3%200 mg NCT02886728 · Phase 3 · combination 15.5%100 mg NCT02886728 · Phase 3 · combination 11.1%200 mg NCT02889796 · Phase 3 12.1%100 mg NCT02889796 · Phase 3 52.1%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 53%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 53.7%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 61.6%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence 0%Filgonitib NCT03926195 · Phase 2 · registry result, not featured evidence 67.6%Filgotinib Darwin 1 NCT02065700 · Phase 2 · registry result, not featured evidence 66.5%Filgotinib Darwin 2 NCT02065700 · Phase 2 · registry result, not featured evidence 0% NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 4.3%200 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 4.3%100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 6.9%50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 7%200 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 1.2%100 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 8.2%100 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 5.9%50 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 7.3%50 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 10.5%25 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence | 0%j NCT01262118 · Phase 1 show 80 more results4.9%5 mg NCT00814307 · Phase 3 11%10 mg NCT00814307 · Phase 3 17.9%5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 20.8%10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 26.5%5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 21.4%10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 n/a: no completion milestone5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 n/a: no completion milestone10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 19.5%5 mg NCT00960440 · Phase 3 —5 mg NCT00960440 · Phase 3 —5 mg NCT00960440 · Phase 3 23.1%10 mg NCT00960440 · Phase 3 —10 mg NCT00960440 · Phase 3 —10 mg NCT00960440 · Phase 3 —5 mg BID NCT01039688 · Phase 3 28%10 mg BID NCT01039688 · Phase 3 27.7%5 mg BID NCT02092467 · Phase 4 31.5%10 mg BID NCT02092467 · Phase 4 —11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination —11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination 10.2%11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination —5 mg NCT00413699 · Phase 3 · registry result, not featured evidence 56.9%5 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 50.8%10 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 3.8% NCT02281552 · Phase 3 · registry result, not featured evidence 36.6%5 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 37.1%10 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 6.9%11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence 7.8%400mg MR + 11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence · combination 9.1%5 mg Twice a Day NCT02147587 · Phase 2 · registry result, not featured evidence 6.3% NCT01359150 · Phase 2 · registry result, not featured evidence · combination 0% NCT00976599 · Phase 2 · registry result, not featured evidence — NCT01059864 · Phase 2 · registry result, not featured evidence · combination 3.8%5 mg NCT00687193 · Phase 2 · registry result, not featured evidence 7.5%10 mg NCT00687193 · Phase 2 · registry result, not featured evidence 3.7%15 mg NCT00687193 · Phase 2 · registry result, not featured evidence 7.5%3 mg NCT00687193 · Phase 2 · registry result, not featured evidence 3.8%1 mg NCT00687193 · Phase 2 · registry result, not featured evidence 8%5 mg NCT00550446 · Phase 2 · registry result, not featured evidence 4.9%10 mg NCT00550446 · Phase 2 · registry result, not featured evidence 5.3%15 mg NCT00550446 · Phase 2 · registry result, not featured evidence 9.6%3 mg NCT00550446 · Phase 2 · registry result, not featured evidence 18.5%1 mg NCT00550446 · Phase 2 · registry result, not featured evidence 17.9%5 mg NCT00603512 · Phase 2 · registry result, not featured evidence 25%10 mg NCT00603512 · Phase 2 · registry result, not featured evidence 17.9%3 mg NCT00603512 · Phase 2 · registry result, not featured evidence 7.1%1 mg NCT00603512 · Phase 2 · registry result, not featured evidence 9.9%5 mg NCT00413660 · Phase 2 · registry result, not featured evidence 10.7%10 mg NCT00413660 · Phase 2 · registry result, not featured evidence 12.5%20 mg NCT00413660 · Phase 2 · registry result, not featured evidence —20 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 12%15 mg NCT00413660 · Phase 2 · registry result, not featured evidence 10.3%3 mg NCT00413660 · Phase 2 · registry result, not featured evidence —3 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 9.9%1 mg NCT00413660 · Phase 2 · registry result, not featured evidence —1 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 4.9%5 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 24.6%30 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 13%15 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 9.3% NCT01484561 · Phase 1 · registry result, not featured evidence —CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence —Methotrexate + CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 2%200 mgj NCT02873936 · Phase 3 show 26 more results3.3%100 mg NCT02873936 · Phase 3 2.4%200 mg NCT02886728 · Phase 3 · monotherapy 3.1%200 mg NCT02886728 · Phase 3 · combination 2.4%100 mg NCT02886728 · Phase 3 · combination 3.6%200 mg NCT02889796 · Phase 3 1.7%100 mg NCT02889796 · Phase 3 12.3%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 13.4%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 14%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 12.2%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —Filgonitib NCT03926195 · Phase 2 · registry result, not featured evidence 33.2%Filgotinib Darwin 1 NCT02065700 · Phase 2 · registry result, not featured evidence 42.6%Filgotinib Darwin 2 NCT02065700 · Phase 2 · registry result, not featured evidence 0% NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 1.4%200 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 0%100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 0%50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 1.2%200 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 0%100 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 3.5%100 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 1.2%50 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 2.4%50 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 3.5%25 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence | —j NCT01262118 · Phase 1 show 80 more results1.2%5 mg NCT00814307 · Phase 3 3.7%10 mg NCT00814307 · Phase 3 6.3%5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 9.1%10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 11.8%5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 11.9%10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 11.2%5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 8.2%10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 9%5 mg NCT00960440 · Phase 3 —5 mg NCT00960440 · Phase 3 —5 mg NCT00960440 · Phase 3 9%10 mg NCT00960440 · Phase 3 —10 mg NCT00960440 · Phase 3 —10 mg NCT00960440 · Phase 3 —5 mg BID NCT01039688 · Phase 3 9.8%10 mg BID NCT01039688 · Phase 3 —5 mg BID NCT02092467 · Phase 4 —10 mg BID NCT02092467 · Phase 4 —11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination —11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination 5.9%11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination —5 mg NCT00413699 · Phase 3 · registry result, not featured evidence 25.9%5 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 23.1%10 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 2.9% NCT02281552 · Phase 3 · registry result, not featured evidence 25.9%5 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 22.9%10 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 1%11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence 1%400mg MR + 11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence · combination 7.3%5 mg Twice a Day NCT02147587 · Phase 2 · registry result, not featured evidence 3.6% NCT01359150 · Phase 2 · registry result, not featured evidence · combination — NCT00976599 · Phase 2 · registry result, not featured evidence — NCT01059864 · Phase 2 · registry result, not featured evidence · combination 3.8%5 mg NCT00687193 · Phase 2 · registry result, not featured evidence 5.7%10 mg NCT00687193 · Phase 2 · registry result, not featured evidence 0%15 mg NCT00687193 · Phase 2 · registry result, not featured evidence 1.9%3 mg NCT00687193 · Phase 2 · registry result, not featured evidence 0%1 mg NCT00687193 · Phase 2 · registry result, not featured evidence 0%5 mg NCT00550446 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00550446 · Phase 2 · registry result, not featured evidence 3.5%15 mg NCT00550446 · Phase 2 · registry result, not featured evidence 3.8%3 mg NCT00550446 · Phase 2 · registry result, not featured evidence 3.7%1 mg NCT00550446 · Phase 2 · registry result, not featured evidence 14.3%5 mg NCT00603512 · Phase 2 · registry result, not featured evidence 14.3%10 mg NCT00603512 · Phase 2 · registry result, not featured evidence 7.1%3 mg NCT00603512 · Phase 2 · registry result, not featured evidence 0%1 mg NCT00603512 · Phase 2 · registry result, not featured evidence 1.4%5 mg NCT00413660 · Phase 2 · registry result, not featured evidence 5.3%10 mg NCT00413660 · Phase 2 · registry result, not featured evidence 5%20 mg NCT00413660 · Phase 2 · registry result, not featured evidence —20 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 8%15 mg NCT00413660 · Phase 2 · registry result, not featured evidence 4.4%3 mg NCT00413660 · Phase 2 · registry result, not featured evidence —3 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 1.4%1 mg NCT00413660 · Phase 2 · registry result, not featured evidence —1 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 1.6%5 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 10.1%30 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 8.7%15 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 1% NCT01484561 · Phase 1 · registry result, not featured evidence —CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence —Methotrexate + CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 4.1%200 mgj NCT02873936 · Phase 3 show 26 more results5.2%100 mg NCT02873936 · Phase 3 8.1%200 mg NCT02886728 · Phase 3 · monotherapy 6.3%200 mg NCT02886728 · Phase 3 · combination 6.3%100 mg NCT02886728 · Phase 3 · combination 7.4%200 mg NCT02889796 · Phase 3 8.3%100 mg NCT02889796 · Phase 3 24.1%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 22.1%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 24.6%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 25.9%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 3.7%200 mg NCT03926195 · Phase 2 · registry result, not featured evidence 12.8%200 mg NCT03926195 · Phase 2 · registry result, not featured evidence 14.3%200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —Filgonitib NCT03926195 · Phase 2 · registry result, not featured evidence 16.9%Filgotinib Darwin 1 NCT02065700 · Phase 2 · registry result, not featured evidence 19.8%Filgotinib Darwin 2 NCT02065700 · Phase 2 · registry result, not featured evidence 0% NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 4.3%200 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 3.5%100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 2.8%50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 2.3%200 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 3.6%100 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 3.4%100 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 0%50 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 0%50 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 2.3%25 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence | 0%j NCT01262118 · Phase 1 show 80 more results—5 mg NCT00814307 · Phase 3 —10 mg NCT00814307 · Phase 3 —5 mg NCT00856544 · Phase 3 1.6%5 mg NCT00856544 · Phase 3 2.2%5 mg NCT00856544 · Phase 3 2.9%5 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 2.2%10 mg NCT00856544 · Phase 3 2.8%10 mg NCT00856544 · Phase 3 2.5%10 mg NCT00856544 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 4.3%5 mg twice daily NCT00853385 · Phase 3 4.2%5 mg twice daily NCT00853385 · Phase 3 5.9%5 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 3.2%10 mg twice daily NCT00853385 · Phase 3 4%10 mg twice daily NCT00853385 · Phase 3 5%10 mg twice daily NCT00853385 · Phase 3 —5 mg NCT00847613 · Phase 3 5%5 mg NCT00847613 · Phase 3 3.5%5 mg NCT00847613 · Phase 3 3.7%5 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 2.3%10 mg NCT00847613 · Phase 3 3.3%10 mg NCT00847613 · Phase 3 3.2%10 mg NCT00847613 · Phase 3 —5 mg NCT00960440 · Phase 3 4%5 mg NCT00960440 · Phase 3 1.5%5 mg NCT00960440 · Phase 3 —10 mg NCT00960440 · Phase 3 4%10 mg NCT00960440 · Phase 3 1.5%10 mg NCT00960440 · Phase 3 10.7%5 mg BID NCT01039688 · Phase 3 10.8%10 mg BID NCT01039688 · Phase 3 25.6%5 mg BID NCT02092467 · Phase 4 28.8%10 mg BID NCT02092467 · Phase 4 3.8%11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination 1.9%11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination 2.9%11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination 10.4%5 mg NCT00413699 · Phase 3 · registry result, not featured evidence 30.8%5 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 29.7%10 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 4.8% NCT02281552 · Phase 3 · registry result, not featured evidence 29.1%5 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 26.7%10 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 2.9%11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence 0%400mg MR + 11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence · combination 5.5%5 mg Twice a Day NCT02147587 · Phase 2 · registry result, not featured evidence 3.6% NCT01359150 · Phase 2 · registry result, not featured evidence · combination 0% NCT00976599 · Phase 2 · registry result, not featured evidence 0% NCT01059864 · Phase 2 · registry result, not featured evidence · combination 3.8%5 mg NCT00687193 · Phase 2 · registry result, not featured evidence 3.8%10 mg NCT00687193 · Phase 2 · registry result, not featured evidence 1.9%15 mg NCT00687193 · Phase 2 · registry result, not featured evidence 5.7%3 mg NCT00687193 · Phase 2 · registry result, not featured evidence 0%1 mg NCT00687193 · Phase 2 · registry result, not featured evidence 0%5 mg NCT00550446 · Phase 2 · registry result, not featured evidence 1.6%10 mg NCT00550446 · Phase 2 · registry result, not featured evidence 7%15 mg NCT00550446 · Phase 2 · registry result, not featured evidence 2.9%3 mg NCT00550446 · Phase 2 · registry result, not featured evidence 5.4%1 mg NCT00550446 · Phase 2 · registry result, not featured evidence 3.7%5 mg NCT00603512 · Phase 2 · registry result, not featured evidence 7.7%10 mg NCT00603512 · Phase 2 · registry result, not featured evidence 3.7%3 mg NCT00603512 · Phase 2 · registry result, not featured evidence 3.6%1 mg NCT00603512 · Phase 2 · registry result, not featured evidence 5.6%5 mg NCT00413660 · Phase 2 · registry result, not featured evidence 1.4%10 mg NCT00413660 · Phase 2 · registry result, not featured evidence 6%20 mg NCT00413660 · Phase 2 · registry result, not featured evidence 0%20 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 8%15 mg NCT00413660 · Phase 2 · registry result, not featured evidence 7.3%3 mg NCT00413660 · Phase 2 · registry result, not featured evidence 0%3 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 2%1 mg NCT00413660 · Phase 2 · registry result, not featured evidence 4.8%1 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 1.6%5 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 4.3%30 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 7.2%15 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 2.1% NCT01484561 · Phase 1 · registry result, not featured evidence 0%CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence 0%Methotrexate + CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 200 mgj nasopharyngitis 10.2% (placebo 4.7%) bronchitis 5.4% (placebo 5.4%) headache 5.4% (placebo 1.4%) NCT02873936 · Phase 3 show 25 more results100 mg headache 5.9% (placebo 1.4%) nasopharyngitis 5.9% (placebo 4.7%) upper respiratory tract infection 5.9% (placebo 4.1%) NCT02873936 · Phase 3 200 mg nausea 12.3% upper respiratory tract infection 10.1% alanine aminotransferase increased 5.5% NCT02886728 · Phase 3 · combination 200 mg nasopharyngitis 9.1% (placebo 5.3%) upper respiratory tract infection 8.6% (placebo 2.9%) nausea 5.5% (placebo 1.5%) NCT02889796 · Phase 3 100 mg upper respiratory tract infection 10.2% (placebo 2.9%) nasopharyngitis 10% (placebo 5.3%) alanine aminotransferase increased 5.2% (placebo 2.3%) NCT02889796 · Phase 3 200 mg covid-19 18.3% nasopharyngitis 13.1% upper respiratory tract infection 11% NCT03025308 · Phase 3 · registry result, not featured evidence 200 mg covid-19 17.3% upper respiratory tract infection 13.1% rheumatoid arthritis 11.9% NCT03025308 · Phase 3 · registry result, not featured evidence 100 mg covid-19 15.3% nasopharyngitis 15.1% rheumatoid arthritis 13.9% NCT03025308 · Phase 3 · registry result, not featured evidence 100 mg covid-19 18.5% rheumatoid arthritis 12.2% upper respiratory tract infection 11.9% NCT03025308 · Phase 3 · registry result, not featured evidence 200 mg nasopharyngitis 7.4% (placebo 7.3%) dyslipidaemia 3.7% (placebo 0%) headache 3.7% (placebo 1.8%) NCT03926195 · Phase 2 · registry result, not featured evidence 200 mg covid-19 15.4% (placebo 0%) ankylosing spondylitis 7.7% (placebo 0%) latent tuberculosis 7.7% (placebo 0%) NCT03926195 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 57.1% (placebo 7.3%) covid-19 42.9% (placebo 0%) alanine aminotransferase increased 14.3% (placebo 0%) NCT03926195 · Phase 2 · registry result, not featured evidence hypertension 15.1% urinary tract infection 14.5% nasopharyngitis 14.1% NCT02065700 · Phase 2 · registry result, not featured evidence mycobacterium tuberculosis complex test positive 16.5% upper respiratory tract infection 15.3% hypercholesterolaemia 12.4% NCT02065700 · Phase 2 · registry result, not featured evidence asthenia 9.5% (placebo 0%) blood creatine phosphokinase increased 4.8% (placebo 0%) dyspepsia 4.8% (placebo 0%) NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 200 mg QD anaemia 5.8% (placebo 0%) upper respiratory tract infection 5.8% (placebo 2.8%) urinary tract infection 5.8% (placebo 1.4%) NCT01894516 · Phase 2 · registry result, not featured evidence 100 mg QD urinary tract infection 8.2% (placebo 1.4%) hypercholesterolaemia 5.9% (placebo 4.2%) hypertriglyceridaemia 5.9% (placebo 1.4%) NCT01894516 · Phase 2 · registry result, not featured evidence 50 mg QD headache 5.6% (placebo 1.4%) hypercholesterolaemia 5.6% (placebo 4.2%) hypertension 4.2% (placebo 5.6%) NCT01894516 · Phase 2 · registry result, not featured evidence 200 mg QD headache 7% (placebo 4.7%) hypercholesterolaemia 5.8% (placebo 0%) hypertension 4.7% (placebo 2.3%) NCT01888874 · Phase 2 · registry result, not featured evidence 100 mg BID hypercholesterolaemia 4.8% (placebo 0%) nasopharyngitis 4.8% (placebo 4.7%) headache 2.4% (placebo 4.7%) NCT01888874 · Phase 2 · registry result, not featured evidence 100 mg QD hypertension 5% (placebo 2.3%) nasopharyngitis 2.5% (placebo 4.7%) upper respiratory tract infection 1.7% (placebo 1.2%) NCT01888874 · Phase 2 · registry result, not featured evidence 50 mg BID upper respiratory tract infection 5.1% (placebo 1.2%) vomiting 5.1% (placebo 1.2%) hypertension 3.4% (placebo 2.3%) NCT01888874 · Phase 2 · registry result, not featured evidence 50 mg QD nasopharyngitis 9.8% (placebo 4.7%) nausea 8.5% (placebo 3.5%) hypertension 3.7% (placebo 2.3%) NCT01888874 · Phase 2 · registry result, not featured evidence 25 mg BID headache 7% (placebo 4.7%) gastroenteritis 5.8% (placebo 0%) nasopharyngitis 4.7% (placebo 4.7%) NCT01888874 · Phase 2 · registry result, not featured evidence | j upper respiratory tract infection 19.4% headache 11.1% urinary tract infection 8.3% NCT01262118 · Phase 1 show 70 more results5 mg upper respiratory tract infection 4.1% (placebo 0%) gastroenteritis 2.2% (placebo 0%) nasopharyngitis 1.9% (placebo 0%) NCT00856544 · Phase 3 5 mg upper respiratory tract infection 3.5% (placebo 0%) diarrhoea 1.9% (placebo 0%) sinusitis 1.6% (placebo 2.5%) NCT00856544 · Phase 3 5 mg upper respiratory tract infection 6% (placebo 0%) nasopharyngitis 5.1% (placebo 0%) diarrhoea 4.4% (placebo 0%) NCT00856544 · Phase 3 10 mg nasopharyngitis 2.8% (placebo 0%) upper respiratory tract infection 2.8% (placebo 0%) oedema peripheral 2.5% (placebo 1.2%) NCT00856544 · Phase 3 10 mg upper respiratory tract infection 5.7% (placebo 0%) blood creatine phosphokinase increased 2.2% (placebo 0%) urinary tract infection 2.2% (placebo 1.2%) NCT00856544 · Phase 3 10 mg upper respiratory tract infection 7.2% (placebo 0%) diarrhoea 3.1% (placebo 0%) headache 3.1% (placebo 2.5%) NCT00856544 · Phase 3 5 mg twice daily nasopharyngitis 2.2% (placebo 1.7%) urinary tract infection 2.2% (placebo 0%) fall 1.7% (placebo 3.4%) NCT00853385 · Phase 3 5 mg twice daily upper respiratory tract infection 3.5% (placebo 0%) nasopharyngitis 3.1% (placebo 1.7%) bronchitis 2.7% (placebo 0%) NCT00853385 · Phase 3 5 mg twice daily upper respiratory tract infection 4.4% (placebo 0%) headache 3.9% (placebo 0%) nasopharyngitis 3.9% (placebo 1.7%) NCT00853385 · Phase 3 10 mg twice daily back pain 0.9% (placebo 0%) fall 0.9% (placebo 3.4%) nasopharyngitis 0.9% (placebo 1.7%) NCT00853385 · Phase 3 10 mg twice daily bronchitis 4% (placebo 0%) abdominal pain upper 2.8% (placebo 0%) arthralgia 2.8% (placebo 0%) NCT00853385 · Phase 3 10 mg twice daily upper respiratory tract infection 3.5% (placebo 0%) headache 3% (placebo 0%) herpes zoster 2.5% (placebo 0%) NCT00853385 · Phase 3 5 mg upper respiratory tract infection 4.7% (placebo 0%) nasopharyngitis 3.6% (placebo 4.9%) bronchitis 0.8% (placebo 0%) NCT00847613 · Phase 3 5 mg nasopharyngitis 5.5% (placebo 4.9%) upper respiratory tract infection 3.2% (placebo 0%) herpes zoster 2.5% (placebo 0%) NCT00847613 · Phase 3 5 mg headache 5.6% (placebo 0%) nasopharyngitis 4.4% (placebo 4.9%) hypertension 3.4% (placebo 0%) NCT00847613 · Phase 3 10 mg bronchitis 2.5% (placebo 0%) nasopharyngitis 2.5% (placebo 4.9%) upper respiratory tract infection 2.5% (placebo 0%) NCT00847613 · Phase 3 10 mg nasopharyngitis 5.6% (placebo 4.9%) urinary tract infection 4.3% (placebo 0%) upper respiratory tract infection 3.8% (placebo 0%) NCT00847613 · Phase 3 10 mg nasopharyngitis 4.1% (placebo 4.9%) cough 2.8% (placebo 0%) diarrhoea 2.5% (placebo 0%) NCT00847613 · Phase 3 5 mg rheumatoid arthritis 3.5% (placebo 3%) bronchitis 3% (placebo 0%) nasopharyngitis 3% (placebo 3%) NCT00960440 · Phase 3 5 mg diarrhoea 6% (placebo 3.8%) nasopharyngitis 3.8% (placebo 3%) upper respiratory tract infection 3.8% (placebo 3%) NCT00960440 · Phase 3 10 mg upper respiratory tract infection 4% (placebo 3%) nasopharyngitis 2.5% (placebo 3%) back pain 2% (placebo 1.5%) NCT00960440 · Phase 3 10 mg headache 6% (placebo 0.8%) nasopharyngitis 4.5% (placebo 3%) diarrhoea 3.7% (placebo 3.8%) NCT00960440 · Phase 3 10 mg BID nasopharyngitis 9.8% blood creatine phosphokinase increased 9.1% upper respiratory tract infection 9.1% NCT01039688 · Phase 3 5 mg BID upper respiratory tract infection 21.9% bronchitis 15.2% urinary tract infection 13.1% NCT02092467 · Phase 4 10 mg BID upper respiratory tract infection 21.8% bronchitis 16.7% urinary tract infection 15.1% NCT02092467 · Phase 4 11 mg arthralgia 2.7% alanine aminotransferase increased 1.9% aspartate aminotransferase increased 1.9% NCT02831855 · Phase 4 · registry result, not featured evidence · combination 11 mg alanine aminotransferase increased 3.8% bronchitis 2.6% nasopharyngitis 2.6% NCT02831855 · Phase 4 · registry result, not featured evidence · combination 11 mg nasopharyngitis 5% upper respiratory tract infection 4.8% nausea 2.9% NCT02831855 · Phase 4 · registry result, not featured evidence · combination 5 mg bronchitis 1 6.3% alanine aminotransferase increased 0% anemia 0% NCT00413699 · Phase 3 · registry result, not featured evidence 5 mg BID upper respiratory tract infection 20.3% urinary tract infection 14.3% bronchitis 12.6% NCT00413699 · Phase 3 · registry result, not featured evidence 10 mg BID upper respiratory tract infection 18.3% nasopharyngitis 15.4% urinary tract infection 13.3% NCT00413699 · Phase 3 · registry result, not featured evidence nasopharyngitis 9.6% NCT02281552 · Phase 3 · registry result, not featured evidence 5 mg BID nasopharyngitis 58% herpes zoster 15.5% fall 13.4% NCT00661661 · Phase 3 · registry result, not featured evidence 10 mg BID nasopharyngitis 68.6% herpes zoster 21% fall 19% NCT00661661 · Phase 3 · registry result, not featured evidence 11mg MR sars-cov-2 test positive 6.9% urinary tract infection 4.9% headache 3.9% NCT04413617 · Phase 2 · registry result, not featured evidence 400mg MR + 11mg MR urinary tract infection 6.8% sars-cov-2 test positive 3.9% headache 2.9% NCT04413617 · Phase 2 · registry result, not featured evidence · combination 5 mg Twice a Day arthralgia 5.5% (placebo 0%) rheumatoid arthritis 5.5% (placebo 15.8%) NCT02147587 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 5.4% (placebo 7.2%) headache 4.5% (placebo 0.9%) dizziness 2.7% (placebo 0%) NCT01359150 · Phase 2 · registry result, not featured evidence · combination fatigue 13.3% (placebo 0%) hypoaesthesia 13.3% (placebo 0%) nausea 13.3% (placebo 7.1%) NCT00976599 · Phase 2 · registry result, not featured evidence dyspepsia 4% (placebo 2.1%) oedema peripheral 4% (placebo 4.3%) oropharyngeal pain 4% (placebo 0%) NCT01059864 · Phase 2 · registry result, not featured evidence · combination 5 mg nasopharyngitis 11.5% (placebo 11.5%) hypertension 5.8% (placebo 0%) dental caries 3.8% (placebo 1.9%) NCT00687193 · Phase 2 · registry result, not featured evidence 10 mg hyperlipidaemia 11.3% (placebo 0%) hypercholesterolaemia 5.7% (placebo 0%) nasopharyngitis 5.7% (placebo 11.5%) NCT00687193 · Phase 2 · registry result, not featured evidence 15 mg nasopharyngitis 14.8% (placebo 11.5%) low density lipoprotein increased 11.1% (placebo 0%) constipation 5.6% (placebo 3.8%) NCT00687193 · Phase 2 · registry result, not featured evidence 3 mg nasopharyngitis 7.5% (placebo 11.5%) headache 5.7% (placebo 1.9%) hypercholesterolaemia 3.8% (placebo 0%) NCT00687193 · Phase 2 · registry result, not featured evidence 1 mg nasopharyngitis 11.3% (placebo 11.5%) fall 5.7% (placebo 0%) abdominal discomfort 3.8% (placebo 1.9%) NCT00687193 · Phase 2 · registry result, not featured evidence 5 mg urinary tract infection 10.2% (placebo 5.9%) diarrhoea 6.1% (placebo 0%) bronchitis 4.1% (placebo 0%) NCT00550446 · Phase 2 · registry result, not featured evidence 10 mg headache 9.8% (placebo 2.9%) diarrhoea 6.6% (placebo 0%) hypertension 4.9% (placebo 2.9%) NCT00550446 · Phase 2 · registry result, not featured evidence 15 mg urinary tract infection 10.5% (placebo 5.9%) bronchitis 7% (placebo 0%) back pain 5.3% (placebo 0%) NCT00550446 · Phase 2 · registry result, not featured evidence 3 mg diarrhoea 8.8% (placebo 0%) back pain 5.9% (placebo 0%) bronchitis 5.9% (placebo 0%) NCT00550446 · Phase 2 · registry result, not featured evidence 1 mg urinary tract infection 8.1% (placebo 5.9%) diarrhoea 5.4% (placebo 0%) dizziness 5.4% (placebo 2.9%) NCT00550446 · Phase 2 · registry result, not featured evidence 5 mg alanine aminotransferase increased 22.2% (placebo 3.6%) aspartate aminotransferase increased 14.8% (placebo 3.6%) stomach discomfort 11.1% (placebo 0%) NCT00603512 · Phase 2 · registry result, not featured evidence 10 mg nasopharyngitis 15.4% (placebo 14.3%) alanine aminotransferase increased 7.7% (placebo 3.6%) blood triglycerides increased 7.7% (placebo 0%) NCT00603512 · Phase 2 · registry result, not featured evidence 3 mg blood cholesterol increased 11.1% (placebo 0%) alanine aminotransferase increased 7.4% (placebo 3.6%) aspartate aminotransferase increased 7.4% (placebo 3.6%) NCT00603512 · Phase 2 · registry result, not featured evidence 1 mg nasopharyngitis 10.7% (placebo 14.3%) headache 7.1% (placebo 3.6%) stomatitis 7.1% (placebo 0%) NCT00603512 · Phase 2 · registry result, not featured evidence 5 mg diarrhoea 12.7% (placebo 3.9%) nasopharyngitis 7% (placebo 5.9%) upper respiratory tract infection 7% (placebo 2%) NCT00413660 · Phase 2 · registry result, not featured evidence 10 mg cough 8.1% (placebo 0%) influenza 6.8% (placebo 2%) nausea 6.8% (placebo 2%) NCT00413660 · Phase 2 · registry result, not featured evidence 20 mg headache 13.4% (placebo 2%) urinary tract infection 9% (placebo 0%) nasopharyngitis 6% (placebo 5.9%) NCT00413660 · Phase 2 · registry result, not featured evidence 20 mg to 5 mg (R) headache 23.1% (placebo 2%) upper respiratory tract infection 15.4% (placebo 2%) abdominal pain upper 7.7% (placebo 5.9%) NCT00413660 · Phase 2 · registry result, not featured evidence 15 mg nasopharyngitis 8% (placebo 5.9%) alanine aminotransferase increased 6.7% (placebo 2%) aspartate aminotransferase increased 6.7% (placebo 0%) NCT00413660 · Phase 2 · registry result, not featured evidence 3 mg nausea 5.5% (placebo 2%) pharyngitis 5.5% (placebo 3.9%) abdominal pain upper 3.6% (placebo 5.9%) NCT00413660 · Phase 2 · registry result, not featured evidence 3 mg to 5 mg (R) upper respiratory tract infection 23.1% (placebo 2%) arthralgia 15.4% (placebo 0%) headache 15.4% (placebo 2%) NCT00413660 · Phase 2 · registry result, not featured evidence 1 mg diarrhoea 14.3% (placebo 3.9%) abdominal pain upper 4.1% (placebo 5.9%) headache 4.1% (placebo 2%) NCT00413660 · Phase 2 · registry result, not featured evidence 1 mg to 5 mg (R) gastritis 9.5% (placebo 0%) nasopharyngitis 9.5% (placebo 5.9%) oral herpes 9.5% (placebo 0%) NCT00413660 · Phase 2 · registry result, not featured evidence 5 mg BID headache 16.4% (placebo 9.2%) abdominal pain upper 6.6% (placebo 0%) nausea 6.6% (placebo 4.6%) NCT00147498 · Phase 2 · registry result, not featured evidence 30 mg BID headache 24.6% (placebo 9.2%) leukopenia 10.1% (placebo 1.5%) nausea 8.7% (placebo 4.6%) NCT00147498 · Phase 2 · registry result, not featured evidence 15 mg BID headache 11.6% (placebo 9.2%) dizziness 5.8% (placebo 1.5%) hypercholesterolaemia 5.8% (placebo 0%) NCT00147498 · Phase 2 · registry result, not featured evidence nasopharyngitis 8.2% (placebo 5.9%) headache 6.2% (placebo 2%) nausea 5.2% (placebo 3.9%) NCT01484561 · Phase 1 · registry result, not featured evidence nausea 16.7% arthralgia 8.3% back pain 8.3% NCT01745055 · Phase 1 · registry result, not featured evidence anemia 16.7% arthralgia 8.3% back pain 8.3% NCT01745055 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 4 versus Phase 2.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eTrial phases differ: Phase 3 versus Phase 2.
- fAssessment timepoints differ: 312 weeks versus 24 weeks.
- gTrial phases differ: Phase 4 versus Phase 3.
- hAssessment timepoints differ: 48 weeks versus 24 weeks.
- iTrial phases differ: Phase 2 versus Phase 3.
- jPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
filgotinib
show 35 more results
show 35 more results
show 23 more results
show 17 more results
show 6 more results
show 6 more results
show 6 more results
show 6 more results
show 6 more results
show 6 more results
show 30 more results
show 30 more results
+ 237 further endpoints in the CSV export.
tofacitinib
show 35 more results
show 113 more results
show 9 more results
show 203 more results
show 17 more results
show 216 more results
show 96 more results
show 210 more results
show 13 more results
show 210 more results
show 13 more results
show 210 more results
+ 654 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: filgotinib's landscape · tofacitinib's landscape